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LILONG GUO. Regulation of Wnt/β-Catenin Signaling in Cardiac Valve
Development and Disease. (Under the direction of RUSSELL A. NORRIS)
ABSTRACT
Non-syndromic Mitral Valve Prolapse (MVP) is a common disease with
associated morbidities and mortality. Affecting 2-3% of the global population,
MVP has become a significant health burden in developed countries.
We recently identified mutations in the cilia gene, DZIP1 in multiple
families with MVP. To initially identify the function of DZIP1 in valve
biology, we performed proteomics-based approaches with the goal of
identifying unique binding partners for DZIP1. These studies revealed a direct
interaction between DZIP1 and the β-catenin antagonist, CBY1. We
hypothesized that DZIP1 suppresses the Wnt/ β-catenin pathway during mitral
valve development through CBY1. Immunofluorescence staining revealed
overlap between DZIP1 and CBY1 protein at the basal body of the primary
cilium. Increase of activated β-catenin was observed in the Dzip1S14R/+ valves.
Co-immunoprecipitation confirmed an interaction between DZIP1, CBY1 and
β-catenin. Ensuing immunofluorescence staining suggested overlap between
β-catenin and the basal body. DZIP1 truncation mutants identified a minimal
CBY1 interaction motif within the C-terminus of DZIP1. A membrane
permeant mimetic peptide against this motif was synthesized and confirmed
xii

as being able to interact with CBY1 and β-catenin. Treatment of chicken valve
interstitial cells with the mimetic peptide resulted in significant decrease in
activated nuclear β-catenin. To test whether this pathway was relevant in the
context of the DZIP1 mutation, we assayed nuclear vs. cytoplasmic β-catenin
expression in Dzip1S14R/+ MEFs. Western blot analysis showed a significant
increase in nuclear β-catenin from the mutant cells. An additional family was
identified with a rare DZIP1 variant within the DZIP1-CBY1 interaction motif.
The mutation resulted in reduced DZIP1 and CBY1 protein stability and a
peptide synthesized with the mutation resulted in an enhanced interaction
between DZIP1 and β-catenin and an inhibitory effect on β-catenin signaling.
Through analysis of nuclear β-catenin expression profiles during cardiac valve
development, we conclude that Wnt/β-catenin signaling is temporally and
spatially regulated. It is down regulated after E13.5 and undetectable in the
adult. However, β-catenin signaling is significantly upregulated in human
myxomatous valves and thus may be a major contributor to disease phenotype.
In conclusion, DZIP1 suppresses Wnt activity to direct mitral valve
development through interacting with and stabilizing CBY1. This study
characterizes the β-catenin expression profile during murine cardiac valve
development and reveals a molecular mechanism, by which mutations in
DZIP1 alter valve development leading to increased β-catenin signaling.
xiii

Altered β-catenin signaling may be an early initiating signal in the
pathogenesis of MVP.

xiv

Chapter 1: Introduction

1.1.

Cardiac Valve Growth and Development

1.1.1.

Cardiac Valve Structure and Function
The four-chambered vertebrate heart has two sets of cardiac valves: the

atrioventricular (AV) valves and semilunar (SL) valves. The AV valves,
which include the mitral and tricuspid valves separate the atria and ventricles.
The SL valves, which include the aortic and pulmonic valves separate the
ventricles from the great arteries at the arterial pole[1].
The AV valves are made up of two (mitral) or three (tricuspid) valve
leaflets, while the three leaflets of SL valves are named as cusps. The other
difference between AV and SL valves, except for the leaflet’s name, is the
supporting apparatus. AV valves are supported by chordae tendineae, which
attach the valve leaflets to the ventricular papillary muscles[2]. The
asymmetric leaflets are hinged to ring-raped annuli. A comparably unique
supporting structure is present in aortic and pulmonic roots forming a fibrous
annulus[3, 4]. Distinguished from AV valves annuli, the aortic valve annulus
is crown-shaped giving rise to the “semilunar” shape of the individual
cusps[5]. The names of the cusps are given by their relationship to the
coronary artery ostia which are left, right and noncoronary cusps. Similar to
AV valves, complete closure of the three cusps during diastole prevents blood
regurgitation. To maintain unidirectional blood flow through the heart, heart
17

valves open and close approximately 40 million times a year and 3 billion
times over an average lifetime[6].
Mature cardiac valves consist of complex stratified connective tissue
which includes three different extracellular matrix layers (Figure 1.1). The
layer termed the atrialis (AV) or ventricularis (SL) is predominantly
composed of radially orientated elastic fibers. This layer provides assistance
in valve tissue movement by allowing extension and recoil of the valve during
the cardiac cycle[7]. The layer adjacent to atrialis (AV) or ventricularis (SL)
is the spongiosa, which is primarily composed of proteoglycans, such as
versican, decorin and biglycan. Proteoglycans in connective tissues serve for
hydration, compliance, viscosity and regulation of collagen fibrillogenesis[8].
Their accumulation in tissues is associated with myxomatous degeneration[9].
Due to the compressible feature of proteoglycans, this layer provides a buffer
region to absorb high force and allows for changes in leaflet shape during the
cardiac cycle[10]. Adjacent to the spongiosa layer is the fibriosa layer, which
is away from blood flow and located on the ventricular side of the AV valve
leaflets and atrial side of the SL cusps. This layer is composed of densely
packed collagen fibers, which provide strength and stiffness to maintain
coaptation during diastole when back pressure stretches the valve leaflet or
cusps[11]. Noticeably, these layers actually contain not only one type of ECM.
18

For example, collagen can be found in both atrialis and fibriosa[12], a network
of elastic fibers also are present in spongiosa[13], and certain types of
proteoglycan such as versican, decorin ,biglycan, tenascin are also observed
in fibrosa and atrialis[13, 14]. The highly organized connective tissue system
provides an indispensable biomechanical force for coping with the pressure
stretches and compression imposed by the blood flow.
Besides ECM, the cells within the valvular tissue play a fundamental role
in maintaining connective tissue homeostasis in the cardiac valvular functions.
Similar to all the other blood-contacting cardiovascular system surfaces, the
valves are lined by a layer of valvular endothelial cells (VECs) and packed
with valvular interstitial cells (VICs).
VECs function in endothelial-to-mesenchymal transition during early
valvulogenesis through transducing various signals have been elucidated
profoundly while its roles in later stage still remain unclear[15-17]. The
transformation of endothelial cells to mesenchymal cells requires the
downregulation of intercellular adhesion junctions such as VE-cadherin. ProEMT-inducing stimuli such as Tgf-β and Notch secreted from adjacent
myocardium coordinate reprogramming of endothelial cells towards a
mesenchymal phenotype. Prototypical EMT-inducing transcription factors
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such as Snail proteins are activated by Tgf-β and Notch and directly repress
VE-cadherin expression by binding to promoters of VE-cadherin[18].
VICs are the most common cells in the valve and are composed of
heterogeneous

embryonic

progenitor

endothelial/mesenchymal

cells,

quiescent VICs (qVICs), activated VICs (aVICs), progenitor VICs and
osteoblastic VICs[19]. Studies have shown that the heterogeneous behavior
and expression of ECM demonstrated by VICs derived from different regions
of valve tissue may be due to their diverse mechanical and extracellular
environments in vivo[20-22].
The complex and well-defined ECM deposition as well as heterogeneous
VICs give rise to the hints that diseased valvular tissues demonstrate altered
ECM localization. The disturbed arrangement of connective tissue leads to
valvular morphological change. (Figure 1.2)
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Figure 1. 1 Overview of microarchitecture of adult cardiac valves
Valve leaflets are composed of three layers of stratified extracellular matrix,
including an elastin-rich ventricularis layer in SL valves (A) or the atrialis
layer in the AV valves (B) shown as yellow, a proteoglycan-rich spongiosa
layer shown as blue and a collagen-rich fibrosa layer shown as black. Valve
tissue is sheathed in a monolayer of valve endothelial cells (VECs) and
interspersed with valve interstitial cells (VICs). Mitral valve leaflet is
supported by chordae tendinae, which attach leaflet to papillary muscles in
ventricle. Adapted from Katherine E. Yutzey, Dvelopment,2020.
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Figure 1. 2 Diseased mitral valve is associated with disorganized ECM,
disrupted VECs and altered VICs
A. Well defined monolayer of VECs sheathing valve tissue and organized
stratified ECM layers. B. Diseased mitral valve showing disrupted interspaces
between ECM layers, disorganized VICs and interrupted VECs. Adapted from
Katherine E. Yutzey, Dvelopment,2020.
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1.1.2.

Endocardial cushion formation
During early vertebrate embryogenesis, the heart tube consists of an

outer layer of myocardial cells and an inner lining of endocardial cells[23-27].
Specialized ECM composed of proteoglycans and glycosaminoglycans
separates the myocardial and endocardial cell layers which is referred as
cardiac jelly (CJ)[28]. Soon after rightward looping of the heart, the
myocardium localized within specific regions of the primary heart tube, the
atrioventricular canal (AVC) and outflow tract (OFT) increase ECM secretion,
of which hyaluronan and chondroitin sulfates are the major components. This
process gives rise to “swellings” of CJ into the lumen of the heart tube. Thus,
the structure termed “endocardial cushion” is formed[1, 28-31]. The AVC or
inlet connects atria and ventricles, and the OFT connects the ventricular
outlets to the great arteries. Paracrine signals stimulate a subset of AVC and
OFT endocardial cells to lose cell-cell contact, leading to their transformation
into migratory mesenchyme. As a result, newly transformed mesenchymal
cells seed the CJ separating endocardium and myocardium and proliferate to
populate endocardial cushions. The process whereby subsets of AVC and
OFT endocardial cells transform into a mesenchyme is called endothelial-tomesenchymal transformation (Figure 1.3)[32, 33].
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Due to the EMT, the CJ between AVC and OFT becomes
mesenchymalized and grows progressively into the lumen of the AVC and
OFT as the primordium of future valve leaflets of the atrioventricular inlet
(mitral and tricuspid valves) and the ventricular outlet (aortic and pulmonary
semilunar valves). The fused atrioventricular cushions (AV cushions) lead to
the eventual formation of the posteroinferior and septal leaflets of the tricuspid
valve and the aortic leaflet of the mitral valve (anterior leaflet). During
superior and inferior cushion fusion, the lateral cushions formed at the right
and left AV junctions accounts for the development of anterior and posterior
leaflets of tricuspid valve and the mural leaflet of the mitral valve[34, 35].
This radical event is dependent on myocardium derived soluble factors to
signal the endocardium[36].
Formation of semilunar valves originates from cushion mesenchyme in
the outflow tract. At 4-5 weeks of gestation, two big swellings in the truncal
region (truncal cushion) and two small swellings in the conal region (conal
cushion) develop in the outflow tract. The exact borderline between the
truncal and conal cushion is almost unassessable in mammals. So, they are
collectively termed conotruncal cushions. The mesenchyme of truncal
cushions is mainly from neural crest cells, where the truncal mesenchyme then
fuses and differentiates to form aortopulmonary septum that divides the aorta
24

and pulmonary trunk. The mesenchymal conal cushions then merge to form a
conal septum, separating the proximal OFT into the right and left ventricular
outlets. The mesenchyme of conal cushions is derived from EMT of the
endocardium, they give rise to the posterior right and left pulmonary valve
cusps and to the anterior right coronary and left coronary aortic valve cusps.
Adjacent to the conotruncal cushions are two other distinct cushions- the
right-posterior and the left-anterior intercalated cushions. They develop
respectively into the posterior noncoronary aortic valve cusps and anterior
pulmonic valve cusps[37] (Figure 1.4).
The endocardial cushions not only give rise to valve structures but also
contribute to the septation of the cardiac chambers. After endocardial cushions
fuse across the midline of the AVC and proximal OFT, the junctional
segments are divided anatomically into right and left or dorsal-ventral
channels or outlets by septal partitions originated from the cushion fusion[3840].
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Figure 1. 3 Epithelial-to-mesenchymal transformation and valve elongation
Endocardial cells in the AV cushions and conal cushions undergo endothelialto-mesenchymal transformation (EMT) and generate mesenchymal cells that
populate the cushions. The mesenchymal cushions then remodel and elongate
themselves to from primitive valves that mature into thin valve leaflets (shown
here for the atrioventricular valves and the semilunar valves). Adapted from
Ching-Pin Chang, Development,2012.
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Figure 1. 4 Cardiac valves development
Looping heart tube: During embryogenesis the cardiac valves develop
through EMT of the endocardial cells. AVC cushion become AV leaflets
and conotruncal cushion and intercalated cushions (not shown) become SL
cusps. Mature heart: separated four chambers and AV/SL structure. Arrows
illustrate the blood flow directions in circulation. Adapted from Peter ten
Dijke, Springer,2013.
27

1.1.3.

Wnt signaling in cardiac EMT and valve morphogenesis
The initiation of endocardial cushion EMT has been marked by
activation of valvular endothelial cells (VECs) in response to a variety of
signals derived from the adjacent networking myocardium[36]. Most of the
signaling pathways crucial for early embryogenesis have been demonstrated
to have an effect on endocardial cushion EMT, including transforming
growth factor beta (TGF-β), WNT, and bone morphogenetic protein (BMP)
ligands[1, 41-44]. This section is mainly focusing on Wnt/β-catenin signaling.
It has been asserted that Wnt signaling is used by cells to influence the

fate or behavior of neighboring cells during development[45-48]. Wnt
molecules are implicated in maintaining stem-cell-like fates in the interstitial
epithelium[49], skin[50], hemopoietic cells[51] and promoting proliferation
in AV cardiac cushion cells[52]. They are considered to signal through
canonical and non-canonical pathways.
Canonical Wnt signaling has been investigated in a large number of
developmental and disease processes. Simply speaking, a Wnt ligand is
secreted and binds to and activates the Frizzled (FZD) class of receptors with
low-density-lipoprotein receptor-related protein (LRP) on the cellular
membrane, through complicated regulatory components, leading to the
28

stabilization and nuclear localization of β-catenin and subsequently activates
Wnt target genes in working with TCF/LEF1 family transcription factors[53].
In the absence of Wnt ligands, β-catenin is sequestered and phosphorylated
by a degradation complex consisting of Adenomatosis polyposis coli (APC),
AXIN, Glycogen synthase 3 β (GSK3 β ), and Casein kinase 1 (CK1).
Phosphorylated β -catenin is targeted for degradation by the proteasome
(Figure 1.5).
Upon Wnt stimulation, this GSK3β/AXIN/APC destruction complex is
inactivated through phosphorylation and subsequently stabilizes β-catenin
and releases it for entry into the nucleus. This pathway is critical for both
endocardial cushion mesenchyme formation and later valve remodeling[18].
Studies in zebrafish revealed the contributions of Wnt/β-catenin signaling in
determining endocardial cell fate. The apc mutant zebrafish hearts which had
constitutive activation of the pathway failed to loop and form excessive
endocardial cushions. Conversely, overexpression of Apc or Dickkopf 1
(Dkk1), a secreted Wnt inhibitor, resulted in the block of cushion
formation[42]. Studies in mice reinforce the observations in zebrafish that
endothelial deficiency of β-catenin demonstrated a lack of heart cushion
29

formation. The impairment of the β-catenin null cells to transform upon TGFβ 2 stimulation implied a cross-talk between Tgf- β and Wnt-signaling
pathways during EMT[54]. However, this study did not clarify whether the
loss of AV cushion mesenchyme in endothelial β-catenin (Ctnnb1)-null mice
results from disrupted Wnt signaling or the distinct adherens junction role of
β-catenin[55]. A recent study using inducible Tet-On transgenic system that
provides spatiotemporal Wnt inhibition through Dkk1 expression suggested
that canonical Wnt signaling is required for proximal outflow tract but not
AVC cushion EMT. The loss of AVC cushions in endothelial β-catenin null
mice is due to loss of adherens junctions. The Wnt signaling actually supports
AVC cushion expansion as being required for AVC mesenchyme proliferation
during EMT and enables mitral valve cushion mesenchyme to respond to
subsequent ECM patterning cues[56].
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Figure 1. 5 Overview of Wnt/β catenin signaling
In the off-state, or absence of Wnt, cytoplasmic β-catenin forms a complex
with APC, Axin, CKI, and GSK-3 and then is targeted for proteasomal
degradation while Wnt target genes are repressed by TCF/LEFs. In the onstate, or presence of Wnt, a receptor complex forms between Frizzled and
lipoprotein receptor-related protein families, which leads to accumulation of
β-catenin in the cytoplasm and nucleus, where it serves as a coactivator for
T CF/LEFs to activate Wnt-responsive genes. CK1, Casein kinase 1; GSK3, glycogen synthase kinase 3; TCF/LEF, T cell-factor proteins/ Lymphoid
enhancer-binding factor; LRP, low-density-lipoprotein receptor-related
protein; APC, adenomatous polyposis coli. Adapted from Evangelisti C, Int.
J. Mol. Sci. 2020.
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Another study by Hulin et al[57] using Axin2 knockout (Axin2LacZ/LacZ or
Axin2-/-) mice offers significant advantage to study the role of canonical Wnt/
β-catenin signaling in valve homeostasis. Axin2 is an inhibitor of canonical
Wnt/β-catenin signaling, the study showed hyperactivated Wnt/ β-catenin
signaling due to loss of Axin2 leads to progressive myxomatous ECM in mitral
valves and aortic valve calcification.
Genetic studies from human myxomatous mitral valves suggested
increases of multiple canonical Wnt/β-catenin signaling components
including Wnt ligand (WNT9A), and receptor (FZD8), transcription factors
(TCF4), and extracellular positive modulators of Wnt signaling (RSPO2),
which is an Wnt/β-catenin signaling agonist through attenuation of DKK1dependent inhibition of Wnt ligands[58-60]. TGF-β2-treated human mitral
valve interstitial cells (MVICs) demonstrated increased nuclear translocation
of β-catenin while total protein levels stay unchanged in keeping with the prior
study showing the cross talk between TGF-β and Wnt/β catenin signaling[54,
60, 61].
The other branch of Wnt signaling is the planar cell polarity (PCP)
pathway, which is regulating the cells’ orientation relative to an axis along the
plane of the tissue. Due to its independence of β-catenin, this is also called
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non-canonical Wnt pathway. The core components of the pathway include
transmembrane protein Frizzled, Vangl, Celsr and cytoplasmic proteins
Prickle and Dvl[62]. Noncanonical Wnt ligands (Wnt5a and Wnt11) bind Fzd
receptor and activate the recruitment of cytoplasmic Dvl to the plasma
membrane to initiate downstream diverse pathways regulating different
aspects of cytoskeleton reorganization in cell movements and polarity
including RhoA, JNK, Profilin[62].
Normal cardiac development is dependent on PCP signaling, and the
disrupted expression of proteins in PCP pathway contributes to heart defects.
Loop-tail (Lp) mutations in Vangl2 abrogated its interaction with Dvl and
results in outflow tract errors during development. Lp homozygotes mice
manifested double-outlet right ventricle defects and double-sided aortic arch
defects[63]. Mutations in Dvl2 gene show the similar OFT defects seen in Lp
mice including double-outlet right ventricle and ventricular septal defects and
the mechanism is thought to influence neural crest cell migration in PCP
signaling[64]. More other studies have demonstrated that the rest PCP
components are interfering the heart development, however, it is interesting
to notice that no genes within the PCP pathway that cause cardiovascular
defects in humans have been described thus far. This is largely due to the
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fundamental role of PCP during very early gastrulation, and individuals with
the mutations might be embryonical lethal[65].
1.1.4.

Maturation of valve development
After formation of endocardial cushion is finished, EMT is stopped and

VECs regain cell-cell contacts and get back an uninterrupted endothelium. At
the same time, the connective tissue within the developing valve structures
goes through extensive remodeling and cells continues to proliferate. The
mature valve structure is made up of highly organized ECM that is
sectionalized into three layers: the fibrosa, spongiosa, and atrialis (AV) or
ventricularis (SL) as described in the first section.
The ECM of endocardial cushions before EMT is rich in hyaluronan, and
the mesenchymal cells in the cushions start to produce collagens and matrix
metalloproteinases (MMPs) 1, 2, 13, which promote cell migration[66-69].
The ECM composition of the mature valves is dependent of the synthetic
activity of the VICs. Genes that encode fibrillar collagens, chondroitin sulfate
proteoglycans and elastin are associated with the stratified ECM of the valve
leaflets during the valve remodeling[3, 70]. At the molecular level during midstages of valvulogenesis, loss of expression of mesenchymal-specific genes,
including Twist1, Tbx20, Msx1, and Msx2, were observed in VICs. in vitro
experiment showed that VICs isolated from pre-fused endocardial cushions
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appear to have decreased differentiation potential as development progresses.
Differentiation markers including Sox9 for chondrocyte and Scleraxis for
tendon cells start to express in the VICs concurrently[71-74]. The complexity
of ECM protein expression and stratification are the structural basis for valve
function throughout life[10, 75]. Loss of the proteoglycan versican results in
endocardial cushion maturation defects. Expressions of MMPs and their
inhibitors, tissue matrix metalloproteinases (TIMPS) have been validated in
the remodeling valves, and increased expression of several of these genes have
been associated with human myxomatous valve disease as being observed
with ECM disorganization[76-78].
1.2.

Primary Cilia

1.2.1.

structure and function
The primary cilium is a microtubule-based organelle that projects from

the surface of the vertebrate cells[79]. Since as early as 1898 when primary
cilium was first discovered, the primary cilium had long been ignored and was
considered to be a vestigial remnant of evolution[80]. As intensive studies
recently brought primary cilia into the spotlight, biologists have gained more
insights of its structure and functions in development, human disease and
cancer[81].
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Sharing similar structure components with other types of cilia (motile
cilia, nodal cilia), primary cilia demonstrate unique constructions which are
closely tied to its function. Structurally, a primary cilium is composed of an
axoneme and basal body. Generally speaking, most cells posse one cilium, an
exception being olfactory sensory neurons where each cell possess about 10
primary cilia[82]. The axoneme of a primary cilium contains a ring of nine
outer microtubule doublets (known as 9+0 axoneme) which differs from
motile cilium containing additional two central microtubule singlets
surrounded by a ring of nine outer microtubule doublets (known as 9+2
axoneme). Besides the central microtubule singlets, motile cilia possess
dynein arms (outer and inner dynein arms) and radial spokes, the structures
essential for and regulate cilium motility[83, 84]. The extension and
maintaining of the axoneme are mediated by IFT (intraflagellar transport)
machinery which transports various of particles along the axoneme. There are
two trafficking systems defined by different compositions and trafficking
directions. The anterograde IFT, moving from base toward cilium tip, is
composed of kinesin-2 motor (contains KIF3A, KIF3B and KAP3) and IFTB
proteins. While the retrograde IFT, moving from cilium tip toward the base,
consists of dynein motor (DYNC2H1 and DYNC2L11) and IFTA
proteins[85]. The two reversed trafficking complexes functions uniquely
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during ciliogenesis. Perturbation of the anterograde IFT blocks cilia formation,
however, disruption of the retrograde IFT leads to shortened cilia[85-89].
The basal body, a barrel structure of nine triplet microtubules, is derived
from the mother centriole (Figure 1.6). During G1 phase, the centriole moves
to the cell surface where it acts as a basal body to initiate ciliogenesis. Then,
the cilia are resorbed during mitosis, and the basal body moves to the spindle
pole and revert to centriole[90]. Basal bodies are absolutely required for
ciliogenesis. One of the crucial functions is that basal bodies provide the
template for the formation of the array of nine microtubule doublets of the
axoneme. Studies showed that basal bodies that lost ninefold symmetry failed
to propagate symmetry information to the axoneme, which had an effect on
the doublets number in axoneme[91, 92]. It is also indicated by the electron
micrographs that the outer doublet microtubules of the axoneme are
contiguous with the triplet microtubules in the basal body[93]. In addition to
acting as a template for microtubules, basal bodies also play a key role in
membrane docking during ciliogenesis through ultrastructural features called
transitional fibers by contacting the cell surface[90]. By forming centrioleassociated vesicles prior to the fusion with plasma membrane, the docking
process is a specialized type of exocytosis[94]. Finally, basal bodies provide
docking stations for proteins during primary cilia biogenesis through the
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specialized structures at its distal end. Elongation of a growing cilium requires
IFT cargo to transport ciliary proteins. Basal body contains recognition sites
to recruit these assembly factors as evidenced by IFT accumulation around
the basal body[95].
Between axoneme and basal body is the transition zone, and transition
fibers, collectively known as “ciliary gate” (Figure 1.6). Structurally, the
transition zone includes Y-shaped links, ciliary necklace, and terminal plate
(often visualized as an electron-dense aggregate on TEM). Y-shaped links act
as connectors between microtubule doublets and primary cilia membrane
microtubule doublets and primary cilia membrane. Ciliary necklace consists
of several parallel strands of intramembrane particles separating terminal plate
from plasma/cilia[96]. In motile cilia, the boundary between the axoneme and
transition zone is referred to basal plate which is considered to participate in
the nucleation of the central microtubules[97]. Because the lack of the central
microtubules, primary cilia do not have this structure. It is proposed that the
transition zone is to regulate ciliary protein composition in Chlamydomonas,
C. elegans and mammalian cells through regulating the trafficking during
ciliogenesis. However, the details of how the proteins are sorted have been
undecided[98-100]. Transition fibers derive from basal body triplet
microtubules forming a “pinwheel-like” structure on TEM cross-sections.
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They are thought to anchor microtubules to the plasm membrane through
CEP164[101, 102] and ODF2. Also, transition fibers may play a role in
docking the IFT and motor proteins required for ciliogenesis as evidenced by
studies showing the localization of IFT52 on transition fibers[95].
Being distinguished from architecture of axonemal microtubules, both
motile and non-motile cilia are prevalently present in multiple tissues and
organs throughout the body regulating key events during development and in
the adult. Motile cilia are mainly used to move extracellular fluid and gametes.
The motility is required to determine embryonic left-right asymmetry though
a generation of extraembryonic fluid flow[103]. Motile cilia present on
respiratory epithelial cells are contributing to mucus clearance[104].
Furthermore, the ependymal flow is also mediated by motile cilia[105]. On
the other hand, primary cilia, lack of dynein arms and radial spokes, are
fundamentally involved in chemo- and mechanosensory process that
coordinate a variety of signaling pathways, such as the pathways mediated by
Hedgehog (HH), G-protein-coupled receptors (GPCR), WNT, receptortyrosine kinases (RTKs) and TGF-β/BMP receptors[79, 106-123].

39

Figure 1. 6 Schematic representation of cilia ultrastructure
Cilium is microtubule-based organelle structurally including axoneme,
transition zone, transition fibers and basal body. On the middle part, is crosssections at axoneme in non-motile (Aka. Primary cilium) and motile cilium.
Non-motile cilium has a 9+0 microtubule composition whereas motile cilium
has a 9+2 microtubule composition possessing dynein arms, radial spokes.
Ciliary motility of motile cilium is regulated by outer and inner dynein arms.
On the left-hand side, is an enlarged immunofluorescence micrograph of a
single primary cilium on an neonatal mouse mitral valve tissue for the cilia
marker Arl 13b (red), the basal body marker γ-tubulin (green). Scale bar = 1
μm. Adapted from Szymanska and Johnson, Cilia, 2012.
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1.2.2.

Primary cilia in cardiac development
Expression of primary cilia in cardiac tissue during development is

conserved across species[124]. Human embryonic and adult heart were also
found to have primary cilia first by R Myklebust, et al in 1977[125]. Later on
the spatiotemporal distribution of primary cilia during heart development have
been described by showing the presence of primary throughout the E9.5
embryonic mouse heart, lining the endothelium of both atrial primordia and
persistence of primary cilia in the atrium and the ventricular trabeculation and
epicardium at E12.5[126], yet no motile cilia were found in the embryonic
heart through transmission electron microscopy (TEM)[127].
The expression pattern of primary cilia during the mitral valves and
aortic valves development have been demonstrated by our previous studies.
Primary cilia were ubiquitously present in e11.5 mouse endothelial cushions.
As AV cushions develop and stratify into valves, the number of primary cilia
decreases and almost are absent on adult tissue (3 months). Whereas the
primary cilia length increases and reaches its peak at P0[128]. During aortic
valve development, primary cilia were present on the OFT cushions at E11.5.
As development proceeds into fetal life, the number of primary cilia decreases,
and length increases reaching its peak at e17.5. They are largely undetectable
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postnatally, similar to what have been observed in mitral valve tissue[129].
Interestingly, these studies about primary cilia spatiotemporal patterns have
indicated that primary cilia were rarely seen on valve endocardium. The reabsorption of cilia in the endothelium of the endocardial cushions is probably
due to the fluid sheer stress as the biomechanical forces exerted by blood flow
are sensed by the endothelium[130-134].
The cilia length is a predictor of proper cilia function due to the findings
of cilia function and several ciliopathies have been associated with defects in
cilia length[135-137]. A number of ciliary genes affecting the elongation of
primary cilia have been linked to congenital heart disease (CHD). Ift88, a
component of the IFT system, is required for the formation and maintenance
of primary cilia axonemes and has been studied extensively. Mice with Ift88
mutations have defects in chamber maturation including atrial septal defects
(ASD), ventricular septal defect (VSD), atrioventricular septal defect (AVSD),
and OFT septal defects[126, 127, 138]. Furthermore, global loss of Kif3a, a
component of kinesin-2 motor (refer to 1.2.1), results in complete lack of
endocardial cushions[126] . In addition, targeted deletion of Ift88
demonstrated a hypoplasia of endocardial cushions[138]. All these studies
suggest that primary cilia are involved in formation and development of
endocardial cushions.
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Studies from our group demonstrated that conditional ablation of Ift88
with NfatC1 Cre which knocked out Ift88 exclusively from endocardial and
endocardial derived cells results in myxomatous mitral valve disease and
bicuspid aortic valves (BAV). The mechanism is still not quite clear, but the
RNA-seq analysis confirmed that loss of primary cilia results in robust
activation of ECM gene pathways. Subsequent IHC showed altered ECM
expansion and deposition in Ift88 deficient valve tissue. These observations
highly suggest that primary cilia are likely to impact valvulogenesis through
restraining ECM production[128, 129].
1.2.3.

Wnt signaling and primary cilia
The Wnt signaling network is critical to valve development. As

discussed above, either up or down-regulated Wnt/β-catenin signaling leads
to morphological change during valvulogenesis. With more and more ciliary
proteins being identified to paly roles in Wnt/β-catenin signaling, there has
been a controversial argument about the link between Wnt signaling and the
primary cilium.
Among them, Dvl regulates activation of the canonical pathway through
inhibiting GSK3β/Axin/APC complex. In this way, Dvl protects β-catenin
from being degraded by proteasome. Early studies showing Inv localized to
cilia and physically interacted with Dvl first connects cilia and the canonical
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Wnt pathway[139-141]. Following research using Wnt-responsive reporter
construct suggested that Inv abrogated the ability of Dvl to activate Wnt
signaling. These studies indicate that canonical Wnt signaling is actually
constrained rather than promoted by events at cilia[140]. Disruption of
primary cilia in mice containing mutations in Kif3a, Ift88 or Ofd1 (an Xlinked gene encoding a basal body protein required for ciliogenesis[142])
resulted in a remarkable increase in cellular response to canonical Wnt
signaling in both cultured mouse embryonic fibroblasts (MEFs) and
embryonic stem cells[143]. However, confounding results were observed in
Ahi1 mutant mice, which showed a loss of basal canonical Wnt signaling
activity resulting in cystic kidney disease[144]. AHI1 in humans encodes
Jouberin, a cilia protein, mutation of which causes a severe multi-organ
ciliopathy including polycystic kidneys[145]. This study might seem to
indicate a positive, rather than negative role for cilia in Wnt signaling.
Some studies argue that there is in fact no role at all for cilia in Wnt
signaling. The study in ift88 mutant zebrafish did not show apparent defects
in Wnt-dependent developmental processes or in expression of known Wnt
target genes while did display the absence of primary cilia[146]. The Ift88,
Ift172, Kif3a and Dync2h1 mutant mice embryos did not show distinguishable
Axin2, a downstream target of canonical Wnt signaling. Using BAT-gal
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transgenic mouse embryo to report canonical Wnt signaling in those mutants
did not show β-galactosidase expression patterns alterations, either[147]. The
Wnt reporter quantification in MEFs generated from wildtype and ciliadefective mice did not find any difference in the response to Wnt ligand, as
well[147]. From the confounding studies, it is very much clear that regulatory
role of canonical Wnt signaling from primary cilia is cell type specific. It is
drastically more subtle than the role of cilia in other signaling pathways, such
as Hh signaling[148].
Additional researches about roles of cilia upon non-canonical Wnt
signaling (PCP) add a further layer of complexity to relationship between cilia
and Wnt signaling. Multiple PCP components are localized to basal body such
as Vangl2 and Dvl2, of which defections result in OFT and ventricular defects
as discussed previously[63, 64, 149]. In support of the idea that non-canonical
Wnt signaling is associated with cardiac primary cilia, ciliary genes such as
Gmap210 was deleted in mice embryos. GMAP210 functions with IFT20 in
the trafficking of ciliary proteins for ciliogenesis. The model demonstrated
cardiac phenotypes resembling those observed in multiple PCP mutants[150].
But this is not direct evidence that the cardiac phenotypes observed in the
Gmap210-/- mouse are associated with defective non-canonical Wnt signaling.
In recent years, the PCP pathway has been considered to be required for the
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orientation of basal bodies involved in the establishment of left-right
asymmetry during embryogenesis[151-153]. However, as PCP components
are also required for basal body assembly/docking, a key question that
remains to be determined is what is required first: intact PCP signaling for
ciliogenesis/basal body positioning, or intact cilium for subsequent PCP
events? Another question that needs to be elucidated is whether the cilium is
responsible for the phenotypes observed in some PCP mutants. Since many of
the ciliary proteins have now been identified in other cellular locations. These
ciliary proteins could be necessary for some other cellular functions. For
example, the basal body protein CBY1 has been reported to directly regulate
β-catenin signaling[154].
1.3.

Mitral valve Disease

1.3.1.

Anatomy
As discussed in the first section that mitral valve (MV) apparatus is a

complex structure composed of the annulus, leaflets, chordae tendineae, and
papillary muscles[155-158]. Detailed anatomical features of MV will be
illustrated here.
The MV annulus is a support compartment in continuity with the aortic
valve through the fibrous aortic-mitral curtain. The two mitral leaflets meet at
lateral and medial commissures and each leaflet is divided into three scallops
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from lateral to medial—in the human. There are two dominant papillary
muscles attached to MV leaflets via chordae tendineae, one anterolateral and
the other posteromedial. Anterolateral papillary muscles engaging in dual
blood supply while posteromedial only has single blood supply which are
more prone to injury from myocardial infarction. The fibrous chordae
tendineae are divided into three types based on their insertion level: primary
chordae insert on the leaflet tips functioning to maintain coaptation of leaflets,
the secondary chordae insert on mid-body of the leaflets providing support
length to leaflets, and the tertiary chordae insert only on the basal part of the
posterior leaflet functioning as structural support. Any pathological alterations
at any level of the MV apparatus can lead to MV dysfunction.
1.3.2.

Mitral valve pathology

1.3.2.1.

Mitral valve stenosis
MV dysfunction contains mainly two types: MV stenosis (MS) and MV

regurgitation. The most common cause of mitral valve stenosis world-wide is
rheumatic heart disease (RHD). It is considered to be associated with an
exaggerated immune response initiated by cross-reactivity between a
streptococcal antigen and the valve tissue[159]. Although it is less common
in western countries, it remains a major public health issue in developing
countries[160]. Other rare etiologies of MS includes systemic inflammatory
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disorders such as lupus erythematous and rheumatoid arthritis, congenital
causes such as parachute mitral valve, double-orifice mitral valve, or
supravalvular mitral ring[161].
1.3.2.2.

Mitral valve regurgitation
The most common cause of mitral valve regurgitation (MR) requiring

surgical intervention in developed countries is MV prolapse (MVP)[161].
MVP can be classified into syndromic and none-syndromic MVP. Syndromic
MVP affect the connective tissue, such as Marfan syndrome, Ehler-Danlos
syndrome, osteogenesis imperfecta and pseudoxanthoma elasticum, which
result from genetic mutations associated with ECM homeostasis. MVP is one
of the manifestations among multiple system impacted symptoms[161]. Nonsyndromic MVP, which primarily affects mitral valve, results from
myxomatous degeneration characterized by abnormal accumulation of
proteoglycan, collagen fragmentation and hyperactivated fibroblast[162].
Over time, leaflets become thickened and floppy which may billow into left
atrium during cardiac systolic cycle. On echocardiography, MV prolapse is
defined as an abnormal leaflet systolic displacement of ≥2 mm above the
mitral annulus plane in a long-axis view[163]. The bulging leaflet gives rise
to back flow of the blood into left atrium during cardiac systolic cycle
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resulting in mitral regurgitation which causes left atrial and left ventricular
volume overload.
Based on the time course of the development of the regurgitation, MR is
divided into acute MR and chronic MR. Acute MR may culminate in
cardiogenic shock due to significantly declines of forward output since much
of the flow is directed to the left atrium. Also, the sudden marked increase in
preload results in a significant increase in LV filling pressures which are
transmitted to the pulmonary circulation leading to pulmonary edema.
Chronic MR has a longer progression from early compensated stage to a
decompensated stage marked by the development of symptoms. Long-term
regurgitation leads to the enlargement of LA, which forms the nidus for the
development of atrial arrhythmias[164].
1.4.

Genetic Discoveries in MVP
MVP is a common cardiac valvular disorder that affects about 2%-3%
of the general population and predisposes the affected individual to a greater
risk for MR, arrhythmia and sudden cardiac death as discussed in previous
section[165-167]. Increased understanding of valvular development, in
combination with current advances in genome-wide association studies, has
led to uncovering of a number of genetic contributors to MVP.
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The first discovery of genetic basis of MVP in humans has occurred
through investigation of Marfan syndrome which gives rise to syndromic
MVP[168]. Mutations in Fibrillin 1 (FBN1), a crucial content of ECM
microfibrils, have been discovered to cause Marfan syndrome[169-171].
Subsequent studies elucidated the molecular mechanism that FBN1 limits the
activation of TGF-β signaling, excessive activation of which leads to ECM
remodeling in the embryonic development of valves[172]. Mouse model
carrying a C1039G mutation in Fbn1 exhibit thickened valves phenocopied
the myxomatous valves in human which was rescued by Tgf-β antagonism
supporting the role for Tgf-β signaling in MVP[173].
Not only in Marfan’s syndrome, MVP appears in other connective tissue
dysplasia such as Ehlers-Danlos (EDS), Stickler, and osteogenesis imperfecta
suggesting the association between genetic mutation of collagen genes and
etiology of MVP. The family of collagen genes found in human valvular
disease to date includes Collagen types I-III, V and XI[174].
By studying families with inherited non-syndromic MVP, three genes
that are associated with MVP have been identified. The first gene linked to
non-syndromic myxomatous valve disease in humans is Filamin A
(FLNA)[175]. This mutation was mapped to Xq28 in 1998 and the causal
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relation of FLNA to X linked MVP was documented by additional four
families[176-179]. FLNA is a structural cytoplasmic protein in the
cytoskeleton and interacts with cell-surface integrins[175]. Expression of
FLNA in the endocardium, epicardium and interstitial cells of the valves have
been characterized, and mouse study with Tie2-Cre confirmed that loss of
endothelial FLNA results in myxomatous mitral valves[180]. In 2015, a lossof-function mutation in the DCHS1, which encodes a member of the cadherin
superfamily and critical for PCP, was identified. This mutation reduces
protein stability and Dchs1+/- mice develop thickened and prolapse mitral
leaflets[181]. The third gene mutation was identified in DZIP1, which is both
essential for ciliogenesis and for Hh signaling[128, 182]. Knock-in mice
manifested myxomatous mitral leaflets which phenocopied human MVP and
ciliopathy indicating that primary cilia contribute to the MVP disease
pathogenesis[128].
In 2015, Dina et al identified the first 3 risk loci for MVP by performing
a meta-analysis of 2 genome-wide association studies in 1412 MVP cases and
2439 controls[183]. Among the genes located within the associated
haplotypes, they identified LMCD1 (Lim and cysteine-rich domains 1),
knockdown of which in zebrafish resulted in increased AC regurgitation and
TNS1 (Tensin 1), a focal adhesion protein involving cytoskeleton organization,
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knockout of which in mice caused enlarged posterior mitral leaflets. This
study suggests new mechanisms involved in MVP regurgitation development.
1.5.

Summary
Cardiac valve development is a complex process involving multiple
signaling pathways. This thesis work is mainly focusing on the canonical
Wnt/β-catenin signaling. As discussed in 1.2.3, Wnt/β-catenin signaling
pathway is indispensable for AVC cushions mesenchymal proliferation and
for OFT EMT. A variety of Wnt signaling components are increased in
myxomatous valve degeneration. Hyperactivation of Wnt/β-signaling during
cardiac valve give rise to myxomatous degeneration. All these evidences
suggest the importance of well-controlled Wnt/β-catenin during cardiac valve
development. But the regulation of the signaling during valvulogenesis has
not been profoundly investigated. The basic question that how β-catenin
distributes during valve development is still not clear. The Chapter 2 of this
thesis work is to clarify the expression profile of β-catenin during murine
valve development. Since membrane bound β-catenin accounts for cell-cell
adhesion, yet nuclear bound β-catenin is responsible for gene transcription, it
is crucial to separate them when considering the roles of β-catenin during
valvulogenesis. This characterization provides a platform where future studies
of β-catenin signaling regulation in valve biology could be conducted.
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Genetic analysis within non-syndromic MVP give rise to valuable clues
in etiology of MVP. One of the genetic mutations that has been validated to
cause

myxomatous

valve

degeneration

so

far

is

DZIP1.

Immunohistochemistry study on myxomatous valve in Chapter 2 revealed
overexpression of β-catenin. To explore how Dzip1 involves in the β-catenin
signaling regulation is the focus in Chapter 3.

53

Chapter 2: Dynamic Expression Profiles of β-Catenin during Murine
Cardiac Valve Development
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2.1.

Introduction
β-catenin is a multifaceted protein with various functions based on its
subcellular localization[184-188]. Expression studies have demonstrated its
presence on the cell membrane, free within the cytoplasm and in the
nucleus[189-193]. Its subcellular functions are likely driven by conserved
structural motifs within the protein, which confer unique protein-protein
interactions[194-196]. The basic protein organization of β-catenin consists of
an amino terminal domain, a central region consisting of 12 Armadillo repeats
and a carboxyl-terminal region[197, 198]. Through the Armadillo repeats, βcatenin serves as both a structural scaffold and signaling protein for a
multitude of interaction partners in adherens junctions, the cytoplasm as well
as the nucleus[199-203].
At the level of the membrane, β-catenin was initially discovered as being
associated with E-cadherin, a critical protein essential for Ca2+-dependent
cell-cell adhesions[204-206]. Through these cadherin-catenin interactions the
adherens junctions become stabilized[207-209]. Upon receiving a Wnt
signaling and/or phosphorylation of β-catenin at specific residues, this
interaction is disrupted, and β-catenin is released from its junctional
components[210-212]. The fate of β-catenin following this release is complex
but likely results in either its cytoplasmic destruction or its nuclear import[213,
55

214]. Although β-catenin does not contain an import or export signal, its
nuclear presence can be driven by either protein chaperones or its binding to
nuclear pore complexes[215-217]. Within the nucleus, β-catenin has been
shown to regulate many aspects of nuclear biology. Most routinely analyzed
are its ability to interact with co-transcription factors in the TCF/LEF1 gene
family[218-220]. It is, however, becoming clear that β-catenin can have
unique TCF/LEF1 independent functions in the nucleus including the
regulation of chromatin remodeling as well as inducing or repressing gene
transcription through association with other co-factors[221-225]. Through the
complexities of the structural and signaling roles of β-catenin, it is no surprise
that perturbation of its expression can impact many different tissues in various
ways. For example, gain and loss of function studies in the heart have revealed
a critical role for β-catenin in cardiac development, especially related to valve
morphogenesis[56, 226].
Although heavily studied, a more thorough characterization of the
expression and localization of either nuclear or membrane β-catenin
throughout cardiac development has yet to be reported. Additionally, scant
data have been shown that clarify the correlation of Lef1 and nuclear β-catenin
at different gestation stages. This information is needed to inform various
cardiovascular phenotypes due to its genetic perturbation. Our detailed
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analysis of β-catenin’s temporal, cell-specific subcellular protein expression
pattern is the focus of this chapter. Herein we report a detailed β-catenin
expression map within the heart, which will facilitate proper interpretation of
gain and loss of function data as well as provide new insight into fundamental
biological processes that are regulated by this important protein.
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2.2.

Results
β-catenin expression during embryonic cardiac development
IHC staining for both activated (β-cateninpS552) and membranous βcatenin revealed dynamic staining patterns that are spatially and temporally
regulated during embryonic gestation. At E11.5, activated β-catenin is
ubiquitously expressed in the nuclei of virtually all cardiac cells including
myocardium, epicardium, endothelium and aortic and atrioventricular valve
progenitor cells (Figure 2.1A-D). A slight, yet consistently lower IHC
intensity of activated nuclear β-catenin expression was observed where the
superior and inferior AV cushions fuse (Figure 2.1D-arrows). In the outflow
segment, activated β-catenin is observed throughout the myocardium and
outflow tract cushions (Figure 2.2E-H). Within the myocardial sleave of the
outflow tract, the cell membrane of myocytes also stained positive for
activated β-catenin (Figure 2.2G, H-arrowheads). This staining seemed
specific for the conotruncal myocardium as no other myocardial regions
within the heart showed membrane staining for activated β-catenin.
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Figure 2. 1 Activated β-catenin expression at E11.5 inflow AV cushions.
Representative images of E11.5 inflow AV cushions immunostained for
activated β -catenin (red), MF20 (green), PECAM (green) and nuclei
counterstained
with
hoechst
(blue).
Myo=Myocardium,
AVC=atrioventricular cushions, epi=epicardium, arrows=endocardium.
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Figure 2. 2 Activated β-catenin expression at E11.5 outflow tract cushions.
Representative images of E11.5 outflow tract cushions immunostained for
activated β-catenin (red), MF20 (green), PECAM (green) and nuclei
counterstained for hoechst (blue). CC=conal cushions, TC=truncal cushions,
arrows=endocardium within outflow tract, arrowheads=myocardium within
conaltruncal myocardial sleeve.
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Much like activated nuclear β-catenin expression, non-phosphorylated
membrane β-catenin was also extensively observed throughout the heart at
E11.5 (Figure 2.3 & Figure 2.4). Within the developing atrioventricular and
outflow tract cushions, membrane β-catenin was observed in the endocardial
and interstitial mesenchyme. Within these structures, the highest degree of
intensity was observed nearest the cushion endocardium. However, in areas
where the major cushions fuse, both PECAM, the adherens junctions marker,
and β-catenin expression appeared dysregulated and with reduced staining
intensity (Figure 2.3D-arrowheads). This was similar to the pattern of
membrane β-catenin in the conal cushions in which the endocardial
epithelium displayed lower staining intensity (Figures 2.4E, F, and Garrowheads). Membrane expression of β-catenin was prominent in all
cardiomyocytes as well as ventricular endocardium and epicardium at this
time point.
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Figure 2. 3 Non-phosphorylated β-catenin expression at E11.5 inflow AV
cushions.
Representative images of E11.5 inflow AV cushions immunostained for nonphosphorylated β-catenin (red), MF20 (green), PECAM (green) and nuclei
counterstained
with
hoechst
(blue).
MYO=myocardium,
AVC=atrioventricular cushions, arrows=endocardial cells with less IHC
intensity, arrowheads=endocardial cells with no IHC intensity.
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Figure 2. 4 Non-phosphorylated β-catenin expression at E11.5 outflow tract
cushions.
Representative images of E11.5 outflow tract cushions immunostained for
non-phosphorylated β-catenin (red), MF (green), PECAM (green) and nuclei
counterstained with Hoechst (blue). CC=conal cushions, epi=epicardium,
myo=myocardium, TR=truncal ridges, arrowheads=endocardium.
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By E13.5, although expression within the mesenchymal cells of the AV
valves is still evident, expression of activated nuclear β-catenin appears
reduced with evidence of perinuclear or membrane expression, especially
within the AV valve endocardium (Figure 2.5B, D- arrowheads).
Additionally, many interstitial cells within the AV valves failed to exhibit
detectable activated β-catenin (Figure 2.5B, D- arrows). Valve interstitial
cells closest to the AV valve endocardium appear to have lost or greatly
downregulated expression of activated β-catenin as nuclear expression is
primarily restricted to a core group of cells within the valve (Figure 2.5 B, Ddotted line). Downregulation of activated nuclear β-catenin was not specific
to the AV valves as we also observed this expression change in the developing
semilunar valves of the outflow tract (Figure 2.6E-H). However, within the
outflow tract valves, expression of activated β-catenin was almost completely
confined to the valve endocardium with only a few interstitial cells staining
positive. Within valve endocardial cells, punctate, nuclear expression was
evident as well as its presence on the cell membrane (Figure 2.6F – boxed
region). Within the E13.5 myocardium activated β-catenin was evident within
the nuclei as well as on the cell membrane. Thus, within the heart at E13.5, a
change in subcellular localization of activated β-catenin is evident as
compared to the E11.5 timepoint, whereby a nuclear to membrane shift of
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protein is observed. In addition, our stainings reveal a profound
downregulation of the phosphorylated, activated form of β-catenin within the
developing mitral and aortic valves.
As our data showed reduced nuclear β-catenin activation at E13.5, we
tested whether expression of non-phosphorylated β-catenin showed a
concurrent up-regulation and/or prominence at the cell membrane. As shown
in Figure 2.7 &Figure 2.8, membrane β-catenin was robust in all areas of the
heart analyzed. The endocardium and subendocardial mesenchyme within the
E13.5 atrioventricular (AV) valves displayed prominent membrane β-catenin
staining. (Figure 2.7A-D). The graded staining pattern within the AV valves
appeared similar to that observed at E11.5, albeit more pronounced at E13.5.
The dotted lines in Figures 2.7A-D demarcate this unique spatial boundary
between two apparent different cell phenotypes based on membrane stainings
for β-catenin. Within the central mass of the valves there appears to be a core
of interstitial cells that display uneven distribution of β-catenin staining. This
is converse to the circumferential, staining of the endocardial and
subendocardial mesenchyme. Much like at E11.5 (Figure 2.3), this pattern of
uneven distribution of staining possibly demarcates an interstitial cell type
that is more primitive and/or shares a phenotype consistent with a less mature
fibroblastic cell. A similar spatial pattern of β-catenin expression on the
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membrane is observed within the outflow tract mesenchyme of the semilunar
valves. One noticeable difference is that the majority of the interstitial
mesenchyme in these valves do not display circumferential β-catenin
expression, but rather a punctate pattern (Figure 2.8F-boxed region). The
outflow tract valve endocardium shows membrane expression of β-catenin
along the basal aspect of these cells, consistent with the presence of adherens
junctions (Figure 2.8F, H-arrows). Within the left coronary cusp, many of the
interstitial cells had very low to undetectable expression of β-catenin (Figure
2.8E-H-asterisks). Outside of the valves, membrane expression of β-catenin
was robust in all areas observed including on cardiomyocytes, the epicardium,
aortic wall and ventricular endocardium.
These expression data correlate with a time point of robust growth within
the heart, consistent with a previously identified role for β-catenin in
proliferation events. It is interesting to note that the endocardium of AV and
conal cushion tissue that are destined to fuse at E11.5 show disorganized or
reduced expression of both membrane and nuclear β-catenin, suggesting that
downregulation of the protein may be required for differentiation of these cell
types or may represent a consequence of compressive mechanical forces
known to occur at these areas. Consistent with this concept of differentiation
is the gradient of membrane expression observed within the AV cushions
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observed at E11.5 and E13.5. Alternatively, the difference in staining intensity
could simply represent a different ultrastructural phenotype of the cell
membrane within the valve interstitium. Previous reports by us and others
have shown that subendocardial cushion mesenchyme are denser compared to
the more dispersed interstitial cells proximal to the myocardium, thereby
likely demarcating at least two different cell types within the AV cushions at
this stage of development. The difference of staining pattern and intensity
within the core of the inflow and outflow tract valves at E13.5 further support
this hypothesis.
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Figure 2. 5 Activated β-catenin expression at E13.5 inflow AV valves.
Representative images of E13.5 inflow AV valves immunostained for
activated β-catenin (red), MF20 (green), PECAM (green) and nuclei
counterstained with Hoechst (blue). AL=anterior leaflet, PL=posterior leaflet,
IVS=intraventricular septum, LV=left ventricle, TV=tricuspid valve.
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Figure 2. 6 Activated β-catenin expression at E13.5 outflow tract SL valves.
Representative images of E13.5 outflow tract SL valves immunostained for
activated β-catenin (red), MF20 (green), PECAM (green) and nuclei
counterstained with Hoechst (blue).
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Figure 2. 7 Non-phosphorylated β-catenin expression at E13.5 inflow AV
valves.
Representative images of E13.5 inflow AV valves immunostained for nonphosphorylated β-catenin (red), MF20 (green), PECAM (green) and nuclei
counterstained with hoechst (blue). AL=anterior leaflet, PL=posterior leaflet,
IVS=intraventricular septum, LV=left ventricle.
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Figure 2. 8 Non-phosphorylated β-catenin expression at E13.5 outflow tract
SL valves.
Representative images of E13.5 outflow tract SL valves immunostained for
non-phosphorylated β-catenin (red), MF20 (green), PECAM (green) and
nuclei counterstained with Hoechst (blue). RA=right atrium, Ao=aorta,
LA=left
atrium,
RC=right
coronary,
LC=left
coronary,
APS=aorticopulmonary septum. Arrows=endocardial cells.
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β-catenin expression during fetal cardiac development
Immunohistochemical stains were performed for both activated (βcateninpS552) and non-phosphorylated β-catenin during fetal cardiac
morphogenesis at E17.5. Within the mitral valves, activated β-catenin was
observed in the nuclei of some cells in a spatial pattern similar to what was
observed at E13.5 (Figures 2.5A-D and 2.7A-D) with some slight,
differences. Within the belly of the mitral leaflets, most interstitial cells
exhibited either undetectable or low levels of β-catenin nuclear expression.
Some, but not all, mitral valve endocardial and subendocardial interstitial cells
displayed weak expression of nuclear β-catenin (Figure 2.9B, D). This pattern
of expression within the valves is reminiscent of the proteoglycan rich
spongiosa region of the mitral valve. Co-immunostains of activated nuclear
β-catenin with hyaluronan binding protein confirmed that nuclear β-catenin is
primarily restricted to this particular valvular region at both E17.5 and E13.5
(Figure 2.18). Within the aortic valves, activated β-catenin was only observed
in a few cells within the hinge regions connecting the aortic cusps to the aortic
wall (Figure 2.10F-arrows). Additionally, a few cells along one side of the
right coronary cusp were positive for nuclear β-catenin expression (Figure
2.10F-arrowhead). Thus, within the fetal mitral and aortic valves, our data

72

would support a continual, gradual downregulation of nuclear β-catenin
during gestation.
Regions outside of the mitral or aortic valves showed prominent nuclear
β-catenin staining including the primary atrial septum, the myocardial rim
lining the mitral-aortic continuity and the inter ventricular septum (Figure 2.9
& Figure 2.10). The myocardium of the left atrium also appears to be positive,
albeit at a much lower staining intensity than the adjacent left ventricular wall
(Figure 2.9C). Within the left ventricular wall, we noticed that nuclear βcatenin within the distal/posterior basal myocardium showed robust staining,
yet in more proximal sections this staining was largely absent (Figure 2.10Garrow). Within the proximal/anterior heart regions, expression is observed
within the myocardial reflections adjacent to the aortic wall (Figure 2.10Garrowhead). These data suggest that β-catenin expression within the left
ventricular myocardium is non-uniform and may demarcate either different
cell populations or spatially dependent functional requirements for these cells.
The staining for membrane-bound, non-phosphorylated β-catenin at
E17.5 exhibited a much different pattern than observed for the nuclear form,
especially within the aortic valves (Figure 2.12). Within the anterior and
posterior mitral leaflets, membrane β-catenin was expressed prominently
throughout the valve endocardium (Figure 2.11A-D-arrows). Cells sub73

adjacent to the atrialis endocardium of the mitral leaflets displayed positive
staining with much less, to undetectable expression within the rest of the
mitral leaflets (Figure 2.11D-arrowheads). Within the aortic valves,
widespread membrane β-catenin was evident on all endocardial cells and most
interstitial cells (Figure 2.12E-H). Unlike the activated form of β-catenin, low
to undetectable membrane staining was evident on interstitial cells within the
hinge regions (Figure 2.12H-boxed region). Unlike the mitral valve, the
staining within the aortic valve does not appear to be confined to one
particular cell layer within the valve cusps. Outside of the mitral and aortic
valves, membrane expression is observed in most cell types including
ventricular endocardium and myocardium and on myocytes within the mitroaortic continuity (MAC) (Figure 2.12E-G). Membrane β-catenin was
undetectable on epicardial cells within the left ventricle or within the
atrioventricular sulcus (Figure 2.11A, B-asterisk).
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Figure 2. 9 Activated β-catenin expression at E17.5 mitral valves.
Representative images of E17.5 mitral valves immunostained for activated βcatenin (red), MF20 (green), PECAM (green) and nuclei counterstained with
hoechst (blue). LA=left atrium, PL=posterior leaflet, AL=anterior leaflet,
LV=left ventricle, IVS=intraventricular septum, PAS=primary atrial septum.
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Figure 2. 10 Activated β-catenin expression at E17.5 aortic valves.
Representative images of E17.5 aortic valves immunostained for activated βcatenin (red), MF20 (green), PECAM (green) and nuclei counterstained with
hoechst (blue). Ao=aorta, LC=left coronary, RC=right coronary, LV=left
ventricle, IVS=intraventricular septum.
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Figure 2. 11 Non-phosphorylated β-catenin expression at E17.5 mitral valves.
Representative images of E17.5 mitral valves immunostained for nonphosphorylated β-catenin (red), MF20 (green), PECAM (green) and nuclei
counterstained with hoechst (blue). Epi=epicardium, PAS=primary atrial
septum, LA=left atrium, LV=left ventricle, AL=anterior leaflet, PL=posterior
leaflet, AVS=atrioventricular sulcus.
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Figure 2. 12 Non-phosphorylated β-catenin expression at E17.5 aortic valves.
Representative images of E17.5 aortic valves immunostained for nonphosphorylated β-catenin (red), MF20 (green), PECAM (green) and nuclei
counterstained with Hoechst (blue). Ao=aorta, LC=left coronary, RC=right
coronary, AL=anterior leaflet, PL=posterior leaflet, MAC=mitro-aortic
continuity, IVS=intraventricular septum.
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Postnatal cardiac β-catenin expression
As either loss of or gain of function of β-catenin has been shown to
contribute to cardiac valvular diseases and postnatal cardiac regenerative
processes, we sought to evaluate expression of β-catenin after birth. As shown
in Figure 2.13, activated β-catenin is only present within a subset of mitral
valve interstitial cells confined to the tips at neonatal timepoints. The mitral
valve endocardium is mostly devoid of positive nuclear staining (Figure
2.13A, B). On the contrary, membrane staining for β-catenin is robust in the
mitral valve endocardium and co-labels with CD31/Pecam at adherens
junctions (Figure 2.13D, E). In adult mice no detectable nuclear β-catenin is
observed within the mitral leaflets whereas the non-phosphorylated β-catenin
isoform is present primarily along the valve endocardial lining of the atrialis
(Figure 2.14). Consistent with previous reports, nuclear β-catenin is
undetectable within the IVS myocardium (Figure 2.14 left), but the nonphosphorylated isoform is observed within the intercalated discs of
cardiomyocytes (Figure 2.14-boxed region). The aortic valves show a similar
pattern for β-catenin expression compared to the mitral valves, with one
exception (Figure 2.15 & Figure 2.16). While membrane bound β-catenin
co-localizes with CD31/Pecam within the aortic valve endocardium as well as
a subpopulation of interstitial cells at the tips of the cusps (Figure 2.15J, K79

arrows), we fail to detect the presence of nuclear β-catenin within the aortic
valves (Figure 2.15 G, H). Similarly, neither form of β-catenin is observed in
the adult aortic valve leaflets (Figure 2.16). At the postnatal timepoints we do
not observe β-catenin expression within the hinge regions of the aortic cusps
but do observe membrane staining within the aortic wall (Figure 2.15 J, Kasterisks). These data demonstrate that activated nuclear β-catenin expression
is only detectable during a developmental and early neonatal window,
whereas membrane bound β-catenin continues throughout life, at least in the
atrial aspect of the mitral valve.
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Figure 2. 13 β-catenin expression at neonatal mitral valves.
Representative images of P0 mitral valves immunostained for both forms of
β-catenin (red), MF20 (green), PECAM (green) and nuclei counterstained
with hoechst (blue). AL=anterior leaflet, PL=posterior leaflet, LV=left
ventricle.
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Figure 2. 14 β-catenin expression at adult mitral valves.
Representative images of 6-month mitral valves immunostained for activated
β-catenin (red), MF20 (green) and nuclei counterstained with hoechst (blue).
IVS=intraventricular septum, AL=anterior leaflet, arrows=endothelium.
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Figure 2. 15 β-catenin expression at neonatal aortic valves.
Representative images of P0 aortic valves immunostained for both forms of
β-catenin (red), MF20 (green), PECAM (green) and nuclei counterstained
with hoechst (blue). RC=right coronary, LC=left coronary, Ao=aorta,
arrows=endocardium, asteroids=hinge regions of the aortic valve.
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Figure 2. 16 β-catenin expression at adult aortic valves.
Representative images of 6-month aortic valves immunostained for both
forms of β-catenin (red), MF20 (green) and nuclei counterstained with hoechst
(blue). RC=right coronary, LC=left coronary.

84

Correlation of β-catenin activities with Lef1
Activated β-catenin can enter the nuclei and bind TCF/LEF transcription
factor to activate transcription of downstream target genes[209, 218, 227].
Therefore, Lef1 is commonly used as a readout marker for β-catenin signaling
[228-233]. More recently, the existence of β-catenin-independent functions
for Lef1 have been documented, bringing into question whether lef1 reporters
represent physiologically accurate measures of β-catenin signaling. To test
this concept, we co-stained activated β-catenin with Lef1 on mitral valve
tissues during embryonic and fetal gestation to determine if they co-localized
with each other (Figure 2.17). During embryonic timepoints, most of the Lef1
positive stained cells were co-stained with nuclear β-catenin. However, a
major discrepancy at this timepoint was that Lef1 was positive only in a subset
of cells, indicating a lef1-independent nuclear role for β-catenin. The staining
at E17.5 showed an even more striking discrepancy between Lef1 and nuclear
β-catenin staining. Lef1 positive cells were observed within nuclei of mitral
valve interstitial cells localized to the tip of the leaflets. However, these
positively stained Lef1 cells showed little detectable β-catenin staining
(Figure 2.17 I-arrows). We rarely observed valve endocardial cells that costained with both markers (Figure 2.17 I-arrowhead). These data support the
contention that although there is a small subset of cells that co-express Lef1
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and β-catenin, the majority of their activities are not mutually inclusive; likely
representing independent roles for these proteins during cardiac valve
development.
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Figure 2. 17 Correlation of β-catenin activities with Lef1.
(A-F). Activated β-catenin (green) and Lef1 (red) were co-stained on E11.5
tissue. Only a subset of activated β-catenin positive cells was co-stained with
Lef1. (G-I) Co-staining Lef1 with activated β-catenin at E17.5. Lef1 positive
cells were localized to the tip of the leaflets showing no appreciable β-catenin
staining (G, I-arrows) and valve endocardial cells that co-stained with both
markers were rarely observed (I-arrowhead). AVC= atrioventricular
cushions, myo= myocardium, epi= epicardium, AL= anterior leaflet, PL=
posterior leaflet, LV= left ventricle.
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Figure 2. 18 Activated β-catenin is prominent in proteoglycan enriched region.
Representative images of E13.5 AV valves and E17.5 mitral valves
immunostained for activated β-catenin (red), HABP (green) and nuclei
counterstained with Hoechst (blue). PL=posterior leaflet, AL=anterior leaflet,
HABP=hyaluronan acids binding protein.
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Human myxomatous mitral valves have increased nuclear β-catenin.
To determine the importance of canonical Wnt/β catenin signaling in
human myxomatous valves, activated and membrane bound β-catenin
antibodies were used to stain human valve tissues. Similar to what was
observed in murine adult tissues (Figure 2.14), unaffected human valve tissue
had undetectable β-catenin expression. However, the human myxomatous
valve had increased expression of both activated and membrane bound βcatenin suggesting a significant increase in its expression (Figure 2.19).
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Figure 2. 19 Human myxomatous mitral valves have increased nuclear βcatenin
Representative images of human myxomatous and health control valve tissues
immunostained for both forms of β-catenin (red) and nuclei counterstained
with hoechst (blue).
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2.3.

Discussion
β-catenin is a member of the armadillo family proteins which plays a
significant role in cadherin-based cell-cell adhesion and is an indispensable
co-activator of Wnt-mediated gene expression[218, 234-236]. The dynamic
regulation of its subcellular distribution, driven by phosphorylation and/or
dephosphorylation events likely dictate its versatile functions[237].
Within the membrane, β-catenin is a critical component of the adherens
junction which helps stabilize intercellular interactions[208]. This Ca2+
dependent cell-cell adhesion event is fundamental for regulating
morphogenetic processes such as endocardial stabilization post-EMT[238,
239]. The function of β-catenin at the membrane is distinct from its unique
transcriptional-regulating properties within the nucleus[240]. Of note, we
propose that care should be given in interpreting Lef1 data and/or reporter
systems that use Lef1 as a readout for β-catenin nuclear activities. Our data
demonstrate that co-expression of Lef1 with nuclear β-catenin is minimal
within the heart. It remains possible that β-catenin is interacting with other
TCF factors within the heart. Future studies should reveal whether these
additional factors are co-expressed and interact with β-catenin and are needed
to activate or repress target gene transcription. Regardless, our expression
studies support a very early embryonic role for nuclear β-catenin, which
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correlates with active growth and proliferation of the heart. As the heart
matures, we observe a reduction in nuclear expression coincident with known
timepoints of reduced proliferation[68]. Previous studies have revealed that
loss of β-catenin or the β-catenin antagonist, Axin2, can result in profound
valvulopathies in mice[57]. Based on our detailed subcellular expression
maps for β-catenin, it seems most likely that the phenotypes have their origins
in altered intercellular communications, and not due to altered nuclear
presence of β-catenin. If true, this concept would be consistent with other
findings in the mitral and aortic valve that have linked disease phenotypes to
altered cell-cell interactions, including recent studies on the cadherin proteins
DCHS1 and CAD-11 [241-243]. Thus, we posit that understanding how
cadherin biology and intercellular interactions drive valve morphogenesis at
the level of the membrane may reveal new mechanisms of development that
are likely to be relevant to human disease phenotypes.
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Chapter 3 DZIP1 regulates mammalian cardiac valve development through a
Cby1-β-catenin mechanism
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3.1.

Introduction
Mitral valve prolapse (MVP) affects 2-3% of the general population and
is associated with secondary co-morbidities such as arrhythmias, heart failure
and sudden cardiac death[166, 244-246]. MVP is characterized as the
billowing of one or both leaflets above the level of the mitral annulus during
cardiac systole. Structural changes of the valve result in an inability for the
valve to be mechanically proficient during the cardiac cycle. These changes
are characterized by alterations in the amount and types of extracellular matrix
(ECM) present within the valves[247]. For example, increased proteoglycan
and collagen deposition are evident with fragmented collagen and elastin
being present. The loss of normal zonal boundaries is evident with expansion
of proteoglycans throughout the valve layers. Valve interstitial cells (VICs)
are thought to contribute to valve degeneration by becoming activated into
myofibroblasts which undergo hyperplasia and produce excess ECM and
growth factor ligands. Over time, the valve becomes thickened and floppy
which results in incompetence, prolapse and mitral regurgitation. Surgery is
the only curative option for patients with severe MVP[247-249].
To date, the molecular and cellular causes of MVP are poorly
understood[247]. Recent genetic studies have revealed a role for primary cilia
during valvulogenesis[250-253], indicating a potential unifying pathway for
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disease initiation. Recently, mutations in the cilia gene DZIP1 were reported
in multiple families with inherited, autosomal dominant non-syndromic
MVP[128]. DZIP1 is a zinc finger protein localized to the basal body and
nucleus and can regulate various downstream pathways involved in hedgehog
and Wnt/β-catenin signaling[254-256]. However, how Dzip1 mutations result
in MVP is unknown.
To investigate the mechanism of DZIP1 in MVP, we identified Chibby1 (CBY1) a binding partner of DZIP1 thorough proteomics analyses. CBY1
is not only a ciliary gene essential for both motile and primary cilia
assembly[257-261], but has also been shown to be a weak β-catenin
antagonist by directly interacting with β-catenin to affect nuclear vs
cytoplasmic shuttling of β-catenin[262-264]. In this chapter we report that a
protein complex consisting of DZIP1-CBY1 and β-catenin are required for
valve morphogenesis and disruption of their interactions cause valve defects
and alterations in ECM production that progress to myxomatous degeneration.
Additionally, identification of a multigenerational family with a rare,
potentially damaging mutation within the DZIP1-CBY1 interaction domain
further support this pathway as causative in patients with MVP.
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3.2.

Results
CBY1 Interacts and colocalizes with DZIP1 in developing mitral valves
To identify direct binding partners for DZIP1 in the heart, yeast twohybrid screens were performed where full length DZIP1 was used as the bait.
We screened 113 million clones from a human embryonic and adult heart
library. Table 1.1 highlights the prevalent DZIP1 interactors in the heart.
PPP2R5A and vimentin had previously been identified as directly interacting
with DZIP1, thus serving as positive controls for the experiment. CBY1, was
the next highest prioritized interactor from our study and was further analyzed.
Co-immunoprecipitations (Co-IPs) confirmed an interaction between DZIP1
and CBY1 in HEK293T cells (Figure 3.1A). Co-expression of CBY1 and
DZIP1 was analyzed by immunohistochemistry (IHC) at E13.5. As shown in
Figure 3.1B and C, Dzip1 and Cby1 show overlap at the basal body of
primary cilia in valve mesenchyme. Whereas Dzip1 is observed both at the
basal body and in the nucleus as we previously reported[128], Cby1 appears
enriched at the basal body. Within the basal body, the pattern of both Dzip1
and Cby1 appear similar and stain only a small fraction of this subcellular
structure, suggesting a function within a discrete portion of the basal body.
We did observe areas in which the two proteins did not co-localize, possibly
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representing unique subcellular expression domains or various snapshots of
expression within shuttling complexes.
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Table 1.1 DZIP1 Interactors
Yeast two-hybrid screening showing previously identified DZI1 interactors
(yellow) and DZIP1-CBY1 interaction (green) with very high confidence
levels (based on # of clones, see Chapter 6 materials and methods).
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Figure 3. 1 Cby1, Identified as Dzip1’s binding partner, localizes to primary
cilia basal body in developing mitral valves
A, Co-Immunoprecipitation (IP) and immunoblotting (IB) analysis of DZIP1
with CBY1 in HEK293T whole-cell lysis. Co-IP was performed using FLAG
or HA antibodies reciprocally. B, Representative images of E13.5 murine
atrioventricular canal cushions (AVC) immunostained for Dzip1 (red), Cby1
(green) and nuclei counterstained with hoechst (blue). Arrows, Dzip1/Cby1.
C, Representative images of E13.5 murine AVC immunostained for Arl13b,
γ-tubulin, Cby1, Dzip1 and nuclei counterstained with hoechst
(blue). Left panel: Arl13b (green), Dzip1/Cby1 (red); Right panel: γ-tubulin
(red), Dzip1/Cby1 (green). Bottom panel: 3D reconstruction of Cby1 (red)
and Arl13b (green) staining on E13.5 murine embryos. Arrows, Cby1/Dzip1.
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Mapping of the DZIP1-CBY1 interaction domain
Various amino and carboxyl-termini deletion constructs for DZIP1 were
generated and expressed in HEK293T cells followed by Co-IP in order to
identify CBY1-interaction motifs. Constructs expressing just the N-terminal
356 amino acids (1-356) failed to interact with CBY1. Likewise, constructs
only expressing the amino acids 613-to the C-terminus (613-867) were unable
to interact with CBY1. However, amino acids 357-612 revealed a positive
interaction between DZIP1 and CBY1 (Figure 3.2A). This region was further
dissected into two polypeptide stretches and tested by Co-IP. As shown in
Figure 3.2B, only region 485-612 harbors the DZIP1-CBY1 interaction motif.
Fine mapping of this region was performed by generating biotinylated 30-35
amino acids overlapping peptides and tested by Co-IP (Figure 3.2C). Within
this region we identified a bipartite interaction motif whereby 2 unique
peptides (amino acids 531-560 and 564-593) were capable of interacting with
CBY1 (P2: 531-560 and P5:564-593). Scrambled and reverse peptides for P5
served as negative controls and failed to show an interaction as expected.
Computational modeling of the peptides revealed similarities between these 2
peptides in conformation indicating a potential likelihood of interacting with
overlapping/similar residues on CBY1 (Figure 3.3A, B). Heatmap analyses
showed that the P2 and P5 peptides are predicted to interact within similar
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regions of the CBY1 protein indicating that structurally, these two regions of
DZIP1 are similarly oriented in 3D space (Figure 3.3C).
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Figure 3. 2 Refined DZIP1-CBY1 interaction domain on DZIP1
A, Co- IP and IB analysis of CBY1 with varies DZIP1 truncated constructs in
HEK293T whole-cell lysis. B, Co-IP and IB analysis of CBY1 with DZIP1(357-484)/DZIP1-(485-612) in HEK293T whole-cell lysis. C, Co-IP and IB
analysis of CBY1 with peptides in HEK293T whole-cell lysis.
Scrambled (SC P5) and Reverse (Rev P5) peptides for P5 served as negative
controls. HEK293T cell lysates served as positive control.
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Figure 3. 3 3D structural predictions for peptides.
A, B, Computational modeling of the two peptides: P2 (A) and P5 (B).
Modeling was generated through RaptorX. C, Heatmap analysis of predicted
peptide binding residues within CBY1 across P2 and P5. Red box, similar
binding residues within CBY1 between P2 and P5.
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DZIP1 peptide interacts with CBY1 and β-catenin.
As Cby1 was previously shown to directly interact with β-catenin[154],
we used Co-IP experiments to test whether Dzip1 was capable of a β-catenin
interaction through a CBY1 linker moiety. As shown in Figure 3.4A, full
length (FL) Dzip1 was able to interact with both CBY1 and β-catenin. When
we tested the amino end (1-356) DZIP1 expression construct, no interaction
with CBY1 or β-catenin was observed, as expected. When the C-terminal 357867 amino acids of DZIP1 were tested, a CBY1 interaction was detected, but
β-catenin was not evident in the IP reaction. This paradoxical observation
indicated that upon CBY1 binding to DZIP1, the amino end of DZIP1 may be
important in stabilizing the β-catenin interaction. It also remains possible that
in the absence of the amino end of DZIP1, the 357-867 DZIP1 polypeptide
folds around CBY1, encasing the protein, hindering interaction with other
proteins. To test this hypothesis, we assayed whether the minimal DZIP1CBY1 interaction motif (peptide 5), was sufficient to pull down the entire
complex. As shown in Figure 3.4B, peptide 5 (P5) was able to coimmunoprecipitate both CBY1 and β-catenin in cultured human valve
interstitial cells. Subsequent immunohistochemistry confirmed that β-catenin
is found at the basal body in developing murine mitral valves at E13.5,
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coincident with the temporal-spatial presence of both Dzip1 and Cby1
(Figure 3.5A, B).
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Figure 3. 4 DZIP1 interacts with β-catenin through CBY1
A, Co-IP and IB analysis of β-catenin with DZIP1 in HEK293T whole-cell
lysis. (1-356), amino acids 1-356 within DZIP1; (357-867), amino acids 357867 within DZIP1; FL, full length DZIP1. HEK293T cells were co-transfected
with full length DZIP1-HA / (1-356) DZIP1-HA/ (357-867) DZIP1-HA and
β catenin-FLAG constructs. Co-IP was performed by pulling down HA tag.
(1-356) DZIP1-HA served as negative control. B, Co-IP and IB analysis of βcatenin with P5 in cultured human valvular interstitial cells (hVICs) wholecell lysis. Biotinylated P5 was incubated with hVICs lysate at 4 ℃ overnight
and was pulled down by streptavidin beads.
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Figure 3. 5 β-catenin locates to primary cilia in developing murine mitral
valves at E13.5
A, Representative images of E13.5 murine AVC immunostained for β-catenin
(red), Arl13b (green) and nuclei counterstained with hoechst (blue). C’&C’’,
arrows, β-catenin. B, Representative images of E13.5 murine AVC
immunostained for β-catenin (red), γ-tubulin (green) and nuclei
counterstained with hoechst (blue). D’, arrows, valvular endothelial β-catenin.
D’’, arrows, valvular interstitial β-catenin.
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Loss of Dzip1 causes increased nuclear β-catenin and Lef1
An interaction between DZIP1, CBY1 and β-catenin combined with our
co-expression studies showing Cby1 is only present at the basal body,
suggested that the DZIP1-CBY1 complex was functioning to sequester βcatenin. To test this hypothesis, we analyzed if loss of Dzip1 in the mitral
valves would release this inhibition. As shown in Figure 3.6A and B, when
Dzip1 is conditionally removed from endocardium and endocardial derived
mesenchyme (Dzip1f/f; NfatC1Cre (+)) that populate the entire mitral valve, a
statistically significant increase in activated, nuclear β-catenin is observed
(p=0.0002) compared to control littermates at P0. This finding correlates with
a significant increase in the β-catenin co-factor, Lef1 (p<0.01), which is
required for its transcriptional regulatory function. Previous reports have
indicated that β-catenin activities may be dependent on the presence of
primary cilia[143, 148]. As Dzip1 conditional knockout and mutant mitral
valves were previously shown to have reduced cilia length[128], it remained
possible that this increase in β-catenin is due to loss of cilia, independent of a
Dzip-Cby1 interaction. Analyses of activated β-catenin in cilia deficient
(NfatC1Cre (+); Ift88f/f) conditional knockout mitral valves failed to reveal a
statistically significant change in activated β-catenin protein expression
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(Figure 3.7). These data indicate that the presence of cilia in the mitral valve
does not directly affect activation of the β-catenin pathway.
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Figure 3. 6 DZIP1 MVP mutation results in increased β-catenin signaling
A, Top: P0 Dzip1f/f; Nfatc1Cre+ murine mitral valves immunostained for pβcateninS552 (red) and nuclei counterstained with hoechst (blue) compared to littermate
control; bottom: P0 murine mitral valves immunostained for Lef1 (red) and nuclei
counterstained with Hoechst (blue) compared to littermate control. B: Left:
quantification of pβ-cateninS552 + cell percentage; middle: quantification of anterior
leaflet cell number; right: quantification of Lef1+ cell percentage. Data are
means ± SD, unpaired two‐tailed Student's t‐test. (n=3/genotype, ***P=0.0002,
**P<0.01, ns, non- significant).
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Figure 3. 7 Regulation of β-catenin is primary cilia - independent
Top panel: Representative images of NfatC1Cre+; Ift88f/f P0 murine mitral valves
immunostained for pβ-cateninS552 (red), MF20 (green) and nuclei counterstained
with hoechst (blue) comparing to littermate control. Bottom panel:
quantification of NfatC1Cre+; Ift88f/f P0 murine anterior leaflet for pβ-cateninS552
+
cell percentage and total cell number comparing to littermate control. Data are
means ± SD, unpaired two‐tailed Student's t‐test. (n=6/genotype, ns, nonsignificant).
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DZIP1 MVP mutation results in increased β-catenin signaling
Our previous data demonstrated that the DZIP1S24R/+ mutation found in
MVP patients and its corresponding mutation in mice (Dzip1S14R/+) resulted in
decreased protein stability and likely loss of function[128]. Thus, we tested
whether this loss of Dzip1 protein would result in a similar increase in nuclear
β-catenin as observed in our conditional Dzip1 knockout mice (Figure 3.2.6).
As shown in Figure 3.8, we observed a significant increase in activated
nuclear β-catenin and its co-factor, Lef1 in the developing mitral valves.
Subcellular fractionation of MEFs isolated from E13.5 Dzip1S14R/+ and
wildtype littermates revealed a similar finding of increased nuclear β-catenin
and reduced fraction of cytosolic β-catenin (Figure 3.8B). Total levels of βcatenin do not change in the MEFs nor do the total number of cells change in
the valves. Coincident with this observation, cycloheximide experiments in
Dzip1S14R/+ MEFs and wildtype controls defined a significant reduction in
Cby1 half-life when Dzip1S14R was expressed. Note, that expression of Dzip1
is undetectable in our Dzip1S14R/+ MEFs even in the presence of a wildtype
allele (Figure 3.9). This is similar to what we observed for the human
mutation in immortalized patient lymphoblasts and indicates that the mutant
protein has a detrimental effect on either the wildtype protein or wildtype
allele[128].
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Figure 3. 8 DZIP1 MVP mutation results in increased β-catenin signaling
A, Left panel: Representative images and quantification of pβ-cateninS552
+
(red) cells on Dzip1S14R/+ mitral valves at P0 comparing to wild-type; right
panel: representative images and quantification of Lef1 + (red) cells on
Dzip1S14R/+ mitral valves at P0 comparing to wild-type. Nuclei were
counterstained with hoechst (blue). Data are means ± SD, unpaired two‐tailed
Student's t‐test. (n=3/genotype, ***P<0.001, **P=0.039
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Figure 3. 9 CBY1 stability is reduced in context of DZIP1S14R presence
Western blots (left) and quantification (right) of cycloheximide experiment
for CBY1 in E13.5 Dzip1S14R/+ MEFs compared to wild type. MEFs were
treated with cycloheximide at 100ng/ml for 48 hours. Data are means ± SD,
unpaired two‐tailed Student's t‐test (n=3/genotype).

114

Identification of a missense mutation affecting the CBY1 interaction
domain in a family with autosomal dominant MVP
Through our whole exome sequencing project of sporadic individuals
and families with non-syndromic MVP, we identified a multigenerational
family with a rare variant in DZIP1, DZIP1C585W/+ (Figure 3.10). The mutation
is rare with a minor allele frequency of 0.0078 and is predicted to be damaging
by SIFT and Polyphen. This particular variant has a CADD (combined
annotation dependent depletion) score of 22.5, which places it in the top 1%
of deleterious single-base changes possible in the entire genome and within
the 95% confidence interval of gene-specific CADD scores corresponding to
high-confidence pathogenic mutations for DZIP1. The mutation segregates
through two generations of the family and all affected individuals harbor the
mutation. None of the confirmed non-MVP individuals have the mutation.
Patient II.2 had indeterminant echocardiography and the status of her mitral
valve was unable to be fully assessed. We tested mutation pathogenicity by
performing cycloheximide experiments on transfected HEK293 cells and
observed that the DZIP1C585W mutation resulted in a decrease in protein
stability with a reduced half-life from 16.97 hours to 1.05 hours (Figure
3.11A). To test whether the mutation also had an effect on CBY1 stability a
similar experiment was performed in a separate CHX assay. As shown in
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Figure 3.11B, expression of DZIP1C585W results in a premature loss of CBY1
expression consistent with our findings in the Dzip1S14R/+ mice.
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Figure 3. 10 Identification of a missense mutation in DZIP1 in a family with
autosomal dominant MVP
Multigenerational family with inherited, autosomal dominant, non-syndromic
MVP. Sanger sequencing identified a single missense mutation of DZIP1,
resulting in a cysteine-to-tryptophan change. Population frequency showing
the rarity of the identified DZIP1 variant in the population.
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Figure 3. 11 DZIP1C585W stability is reduced and CBY1 stability is reduced in
the context of DZIP1C585W
A, Western blots (left) and quantification (right) of cycloheximide experiment
for DZIP1C505W compared to DZIP1 in HEK293T whole-cell lysis. Data are
means ± SD, unpaired two‐tailed Student's t‐test. (n=3, **P<0.01). B,
Western blots (left) and quantification (right) of cycloheximide experiment
for CBY1 in presence of DZIP1C585W compared to presence of DZIP1 in
HEK293T whole-cell lysis. Data
are means ± SD, unpaired two‐tailed
Student's t‐test. (n=3, **P<0.01).
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MVP DZIP1C585W mutation alters protein structure and binding to βcatenin and CBY1
A peptide containing the C585W mutation was synthesized and is
designated P5’ since its sequence is identical to that of the P5 peptide with the
exception of the cysteine to tryptophan change. This peptide was tested for its
ability to alter interactions with the CBY1-β-catenin complex. As shown in
Figure 3.12A, both P5 and P5’ were capable of interacting with CBY1 and βcatenin. However, in all repeated experiments (N=5), the P5’ mutant peptide
demonstrated greater band intensity on the Co-IP reactions, suggesting an
increased affinity for CBY1 and β-Catenin. This result was confirmed in
transfected HEK293 cell lines as well as primary mitral valve interstitial cells
during development. This result was strikingly similar to what we observed
between P5 and the P2 segment, with the P2 peptide showing enhanced
binding compared to P5 (Figure 3.2). Protein modeling and comparative
structural predictions for each of the peptides was performed using RaptorX.
Secondary and tertiary models for each of the peptides revealed a similar
overall structure between P2 and P5’ (Figure 3.12B). Quantification of data
obtained from structure modeling indicated that the cysteine to tryptophan
(C585W) point mutation in the P5 subunit causes a drastic change in protein
tertiary structure (TM Score = 0.1780) compared to wild type. This
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modification renders the P5 C585W mutant more structurally similar to the
P2 WT subunit (Lali: 18; RMSD: 2.28; TM Score: 0.3925) compared to the
P5 WT subunit (Lali: 7; RMSD: 1.90; TM Score: 0.1780). Therefore, although
the mutation causes faster degradation of the full-length protein, it is
structurally more similar to the P2 region and confers increased binding to the
CBY1 and β-catenin complex.
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Figure 3. 12 MVP DZIP1C585W mutation alters protein structure and binding
to β-catenin and CBY1
A, Co-IP and IB analysis of P5 and mutant P5 (C585W) with CBY1 in
HEK293T whole-cell lysis and cultured hVICs whole-cell lysis. P5’, mutant
P5 (C585W); Rev P5, reversed P5; SC P5, scrambled P5. Biotinylated
peptides were incubated with cell lysis overnight at 4 ℃, and peptides were
pulled down by streptavidin beads. B, 3D modeling of P5/P5’/P2 showing
overall similarity between P2 and P5’. Venn diagram: quantification of
modeling data indicating P5 C585W mutant is more structurally similar to the
P2 WT subunit compared to the P5 WT subunit.
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β-catenin transcriptional responses are regulated through Dzip1 decoy
peptides
To determine whether transducing cells with these minimal interaction
motifs could affect downstream β-catenin activities, we synthesized various
peptides based on our Co-IP data and human DZIP1 mutation. Peptides for
the P5 region as well as mutant P5 (P5’) and a P5 reverse peptide were
synthesized with a cell-penetrating TAT peptide sequence and a 5-FAM
moiety for fluorescent visualization at the amino terminus. Peptides were also
biotinylated to be able to confirm interaction with CBY1 and β-catenin. As
shown in Figure 3.13, the 5-FAM-TAT labeled P5 was capable of interacting
with both CBY1 and β-catenin in valve interstitial cells whereas the reverse
peptide was not.
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Figure 3. 13 TAT conjugated P5 forms complex with CBY1 and β-catenin in
cVICs
Co-IP and IB analysis of β-catenin with TAT conjugated P5 in cVICs wholecell lysis. TAT conjugated P5 was incubated with cVICs lysate at 4℃
overnight and was pulled down by streptavidin beads. Reverse P5 served as
negative control. Rev, reverse P5. TAT conjugated peptides on the gel were
imaged under daylight 488.
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To test whether the peptides function to disrupt β-catenin activities
within the cell, valve interstitial cells were transfected with the TOP flash βcatenin reporter plasmids. Forty-eight hours post-transfection, valve
fibroblasts were stimulated with P5 (1μM, 10μM), P5’ (1μM) or reverse
peptide (high dose 10μM). As shown in Figure 3.14A, membrane permeant
peptides were able to traverse the cell membrane and enter the cytoplasm. Cell
viability and substrate attachment were not grossly affected with peptide
administration. Localization of the peptides can be seen perinuclear and along
the cell membrane. Presence of the peptides within the nucleus are not evident,
suggesting potential retention of β-catenin outside of the nucleus. Luciferase
readouts from the TOPflash reporter confirmed a significant reduction in βcatenin activities when treated with both the P5 and P5’ mutant peptides at
1μM dose (Figure 3.14B). P5 treatment at 10μM dose resulted in a complete
block in TOPflash luciferase activation whereas the reverse peptide had no
significant effect at this higher dose. Interestingly, the mutant P5’ peptide was
not as robust in repressing the reporter as the wild-type, even though it showed
enhanced interaction with the CBY1/β-catenin complex by biochemical
approaches.
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Figure 3. 14 Dzip1 decoy peptides disrupts β-catenin transcriptional responses
in vitro.
A, Representative images of P5/P5’/P5 Rev treated chicken valvular
interstitial cells (cVICs) for 24 hours at 10 μM. cVICs were transfected with
TOP/FOPflash reporter construct for 48 hours before peptide treatment. P5’,
C585W mutant P5; P5 Rev, reverse P5. B, Luciferase assay of P5/P5’/Rev P5
treated cVICs. β-Gal was used as internal control. Data are means ± SD,
unpaired two‐tailed Student's t‐test (n=3).
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Enhanced MMP2 expression and altered extracellular matrix deposition
in Dzip1S14R/+ and Cby1+/- postnatal mitral leaflets
Enhanced Wnt/β-catenin signaling has been observed in human
myxomatous valves[60, 265, 266]. Hyperactivated β-catenin can promote
endothelial-to-mesenchyme transformation (EMT), endocardial proliferation,
ECM remodeling and myxomatous degeneration of mitral valves[56, 57, 267].
In this study as well as our previous reports on Dzip1 mutations, we observe
similar findings of increased β-catenin activities within the valves during
development in a model (Dzip1S14R/+) that was previously validated as having
myxomatous valves and MVP[128]. For this study, we initially focused on
MMP2 a known transcriptional target of β-catenin signaling that is also known
to be upregulated in mitral valve disease. As shown in Figure 3.15, we
observe increased MMP2 within the interstitium of Cby1 heterozygote
(Cby1+/-) mitral valves by postnatal day 0. This finding of increased MMP2
was also observed in the Dzip1S14R/+ model of MVP. Although our previous
RNAseq data showed an increase in collagen I mRNA at this timepoint, IHC
in both Cby1 and Dzip1 models show a loss of collagen protein within the
valve. The reduction of collagen I, a known target of MMP2 enzyme activity
was striking, especially along the atrialis of the mitral leaflets and is indicative
of a potential increase in collagen fragmentation as is documented in human
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myxomatous

valves.

Interestingly,

periostin,

a

known

β-catenin

transcriptional target is also upregulated in the Cby1+/- valves, which is
consistent with findings in human myxomatous valves and in hyperactive βcatenin murine models.
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Figure 3. 15 Enhanced MMP2 expression and altered extracellular matrix
deposition in Dzip1S14R/+ and Cby1+/- postnatal mitral leaflets
A. Representative images of Cby1+/- P0 anterior leaflet immunostained for
collagen I (red), MF20(green), periostin (red), MMP2 (green) and nuclei
counterstained with hoechst (blue) comparing to wild type (N=3/genotype).
B. Representative images of Dzip1S14R/+ P0 mitral valves immunostained for
collagen I (red), MF20(green), MMP2 (green) and nuclei counterstained with
hoechst (blue) comparing to wild type (N=3/genotype). Dotted line highlights
the MMP2 enriched area where collagen I was largely invisible.
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3.3.

Discussion
The genetic causes of mitral valve prolapse are only now beginning to be
discovered. Once disease genes are identified, it will be important to identify
the role that these genes play in disease initiation and progression. We recently
identified mutations in the DZIP1 gene in multiple families with inherited non
syndromic mitral valve prolapse. Through CRISPR-Cas9 genome editing, a
murine model for non-syndromic MVP based on a human mutation was
generated (Dzip1S14R/+). Utilizing a combination of proteomic based
approaches with in vivo and in vitro studies, our findings reveal a mechanism
by

which

myxomatous

degeneration

may

occur

through

altered

developmental pathways that invoke both ciliogenesis and β-catenin signaling.
Previous studies have indicated that primary cilia can regulate canonical
Wnt/β-catenin signaling[143, 148]. This is thought to occur through
localization of Wnt receptors on the axoneme of the primary cilia and/or
within the ciliary clefts. However, within cilia deficient mitral valves at P0,
our studies did not reveal a significant change in activated nuclear β-catenin.
Thus, our findings in our Dzip1 models of increased β-catenin/Lef1 signaling
highlights cilia-independent regulation of β-catenin pathways.
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Our recent studies have highlighted a dynamic expression pattern
between nuclear and membrane bound β-catenin[265]. Whereas nuclear βcatenin is present during early embryonic development, a shift to the
membrane is observed during fetal gestation and is maintained after birth.
This likely highlights the multifaceted role for this protein in both nuclear and
membrane function. Mechanisms by which this nuclear vs cell membrane
decision is made are not well understood, but likely critical for restricting βcatenin’s transcriptional function. Our studies highlight the unique possibility
that β-catenin is held at the basal body through a Dzip1-Cby1 complex. CoIP studies confirmed the formation of this complex and identified unique
protein motifs that are critical for this interaction to occur. Generation of
membrane permeant peptides of the Dzip1-Cby1 interaction motif were
sufficient to potently suppress β-catenin transcriptional regulation in vitro.
However, it is unlikely that the peptides would confer sufficient structure to
restrict the entire peptide-Cby1-β-catenin complex to the basal body. It is
more likely that the interaction of the Dzip1-decoy peptide facilitates
stabilization of a Cby1-β-catenin complex and inhibits nuclear shuttling
independent of being sequestered at the basal body. This is further supported
by our anecdotal evidence showing that loss of Dzip1 and/or mutations within
the Dzip1-Cby1 interaction domain results in decreased protein stability
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concomitant with increased nuclear β-catenin and upregulation of
transcriptional activities.
Whole exome sequencing identified a multi-generational family with a
rare, damaging variant in the DZIP1-CBY1 interaction motif. Peptide
analyses and Co-IP studies revealed that this mutation altered the 3D structure
of the protein and conferred a paradoxical increase in Cby1-β-catenin
interactions. This should theoretically result in an increase in the stability of
the complex and a reduction in β-catenin activity. However, this is
confounded by our data showing that the Dzip1C585W mutation results in a
profound reduction in protein half-life and premature degradation of CBY1
protein. Thus, although the DZIP1C585W mutation appears to enhance an
interaction with the complex, the reduced protein expression results in an
overall loss of function, consistent with our other MVP-identified mutation,
DZIP1S24R and our Dzip1 conditional knockout mice.
How altered β-catenin signaling may lead to a myxomatous valve and
mitral valve prolapse is poorly understood. Previous reports have shown that
either loss or gain of β-catenin function can result in a myxomatous
phenotype[54, 56, 57]. In the context of Dzip1 and Cby1, our data show that
loss of either of these genes impairs ciliogenesis (ref 12 and Figure 3.16).
RNAseq and GO analyses by us and others have shown that loss of cilia during
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development results in transcriptional activation of numerous ECM genes
including collagens and proteoglycans. In the context of increased collagens,
one might expect to observe a fibrotic valve. Certainly, this occurs in the
context of various other valve disease such as serotonin or drug-induced (e.g.
fenfluramine, ergotamine) valvulopathies where the valves show stiff “stuckon plaques” and clear evidence of fibrosis. The phenotypes of these valves are
very different from a floppy myxomatous valve, which is defined as having
increased proteoglycans as well as fragmented collagen and elastin. This
highlights that additional signaling pathways are likely in play to explain the
fragmentation of collagen and the loss of properly stratified ECM boundaries.
In this context, fragmentation of collagen would permit encroachment of
proteoglycan proteins that can move via interstitial fluid flow within affected
regions of the valve, particularly within the fibrosa. We believe our
observation of increased MMP2 in our Dzip1 and Cby1 deficient mitral valves
is significant since MMP2 is a direct target of β-catenin/Lef1 transcriptional
regulation. Major substrates for this enzyme are collagens I, III, IV, V, VII,
elastin and TGF-β. Transcripts for each of these ECM genes are increased in
both of our Dzip1 and Ift88 cilia deficient mice. However, there is an
important discrepancy to note. The Ift88 conditional knockout (NfatC1Cre (+);
Ift88f/f) mice show robust increases in collagen I transcript and protein at P0.
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This study paired with our previous study paradoxically shows that while
Dzip1S14R/+ and Dzip1 conditional knockout mice (NfatC1Cre (+); Dzip1f/f) have
increased transcripts for collagen and elastin genes, overall valvular collagen
I protein levels are lower. The most likely explanation for this finding is that
in a mutated Dzip1 tissue, increased β-catenin activity leads to upregulation
of MMPs and subsequent proteolysis of collagens and elastin. Our study
highlights that Dzip1 mutations result in a shift in the balance of ECM
synthesis and destruction through loss of cilia and/or increased β-catenin
signaling. This altered ECM homeostasis eventually leads to the generation of
a myxomatous phenotype that is incompatible with normal valvular function.

133

Figure 3. 16 CBY1 is necessary for ciliogenesis during valve development
Top panel, representative images of Cby1+/- P0 anterior leaflet immunostained
for Arl13B (red), γ-tubulin (green) and nuclei counterstained with hoechst
(blue) comparing to littermate control. Middle panel, representative images of
Cby1+/- P0 anterior leaflet immunostained for acetylated-tubulin (red), γtubulin (red) and nuclei counterstained with hoechst (blue) comparing to
littermate control. Bottom panel, quantification of primary cilia length and
percentage of ciliated cells for Cby1+/- P0 anterior leaflet compared to
littermate control.
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Chapter 4 Future directions
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4.1.

β-catenin expression profile during valvulogenesis
In Chapter 2, we used antibody which targets endogenous level of βcatenin only when phosphorylated at Ser552. This phospho-β-catenin (Ser552)
specifically locates to nucleus. As a transcription co-activator, nuclear βcatenin binds Tcf/Lef1 family member to activated downstream Wnt target
genes. But we did not observe fully overlapping of Lef1 and phospho-βcatenin (Ser552) from IHC. The activities between Lef1 and β-catenin seemed
to be mutually exclusive. Even though studies have shown the Lef1
independent β-catenin pathway and β-catenin independent Lef1 pathway,
questions still remain unsolved that whether phospho-β-catenin (Ser552)
interacts with other Tcf/Lef1 family members such as Tcf1/Tcf3/Tcf4.
Additional immunostainings for those members could be done through
development to determine their co-localization with phospho-β-catenin
(Ser552). Except for Ser552, there are other different phospho sites on βcatenin dictating its nuclear localization, including Ser191, Tyr393, Ser 605,
Ser675. The other question remained unknown is whether these
phosphorylated β-catenin are present on valve tissue during development and
if so, what is their association with different Tcf/Lef1 family members. Future
study could use Mass Spectrometry to map out the phosphorylation sites from
valve tissues at different developmental stage. Ensuing Duolink PLA
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technique on valve tissue could be used to determine the interactions between
β-catenin and Tcf/Lef1 family members.
Immunofluorescence stainings in Chapter 2 are descriptive data. We
know little about the mechanism behind the intriguing β-catenin expression
patterns. In E13.5 AV valves, activated β-catenin are restricted within the
central mass of the tissue and low to non-detectable staining is observed
within subendothelial cells. This demarcates at least two different cell types.
No studies have been done to characterize these two cell types despite they
are all interstitial fibroblasts. The drastically different activated β-catenin
expression patterns between the two subsets of cells indicate the different
biological events these cells may go through. This information will be critical
to shed a light on the VICs biogenesis and valvulogenesis. Future studies
could use single-cell RNA-seq analysis to evaluated cell heterogeneity of
VICs at E13.5. Flow cytometry could be used to sort cells using specific βcatenin antibody.
Another question that is worthy for future study is why activated βcatenin starts to present on endothelial cell membranes at E13.5 AV and aortic
valves. The translocation from nuclei to cell membrane is highly associated
with additional phosphorylation event mediated by other kinases. To test this,
we could use Tie2-GFP mice to isolate VECs through fluorescence activated
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cell sorting (FACS). Mass Spectrometry could be used to identify new
phospho sites.
4.2.

Regulation of Wnt/β-catenin signaling through Dzip1
In the 3rd Chapter, we identified a novel mechanism about how β-catenin
is sequestered by Dzip1-Cby1 complex in cytoplasm. A segment of Dzip1
protein (P5) is capable to substitute for Dzip1. The P5-Cby1 complex is able
to sequester β-catenin in cytoplasm in vitro. The interesting phenomenon is
that the mutant P5 (P5’) seems to have higher affinity to Cby1/β-catenin than
wild type P5 according to stronger Cby1 signal detected from Co-IP. This
leads to the postulation that mutant P5 should sequester more β-catenin in
vitro and the luciferase reporter read out should be lower than wild type P5.
But the fact is somehow on the contrary to our expectation that P5’ treated
cells actually had a higher luciferase reporter read out than wild type P5. The
cause is most likely due to the decreased stability of the P5’. Despite the
higher affinity to β-catenin, P5’ gets degraded faster. The shortened P5’halflife counteracts its inhibition on β-catenin, which leads to a higher β-catenin
activity than wild type P5 in vitro. As mutant Dzip1 protein has a shortened
half-life, the mutant peptide might have the same fate. In order to test the that,
future study could use fluorescence-HPLC (High Performance Liquid
Chromatography) to measure the half-lives of both peptides.
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The identification of the P5 to inhibit β-catenin signaling is not only
critical for valvular disease treatment, but important for cancer suppression.
One of the human cancers caused by Wnt/β-catenin signaling hyperactivation
is colorectal cancer (CRC). The other avenue of future direction is to test the
effect of this peptide to inhibit hyperactivated Wnt/β-catenin signaling in CRC.
We have detected the expression of both CBY1 and DZIP1 in Caco2 (human
colorectal adenocarcinoma cells) cell lysates. Validation of CBY1-DZIP1-βcatenin complex in Caco2 could be done through Co-IP. Future studies could
be done by incubating the Caco2 cells with P5 and control peptide and
determine the localization of β-catenin by ICC. Western blot could be used to
determine the nuclear β-catenin and cytoplasmic β-catenin expression.
Anticipated results would be less nuclear β-catenin and more cytoplasmic βcatenin with P5 than control peptide.
Another segment of DZIP1 that is able to interact with CBY1 is peptide
2 (P2). A comparison between P2 and P5 could be studied in the future. We
could compare the stability through fluorescence-HPLC. We could also
compare the binding affinity to β-catenin and CBY1 through quantitative GST
pull down. Through comparisons, we can select a more superior candidate to
be potentially investigated clinically. The whole advantage of using the
peptide to antagonize β-catenin signaling is that the peptide brings less side
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effects. The cell penetrating peptide (CPP) is a substitute for DZIP1 in the βcatenin sequestration complex. It does not affect DZIP1’s other biological
functions. Trough titration experiment, we could be able to find a proper
dosage to offset the hyperactivated β-catenin signaling and keep the signaling
working at a normal level.
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Chapter 5 Overall discussion
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Wnt/β catenin signaling is one of the most important developmental
signaling pathways that controls cell fate decisions and tissue patterning
during early embryonic and later development. β-catenin is the key effector
responsible for transduction of the signal to the nucleus and it triggers
transcription of Wnt-specific gene responsible for the cell fate decision in
many cells and tissue. Especially in heart valve development, β-catenin
involves in the proliferation in AVC EMT and hyperactivated β-catenin leads
to myxomatous ECM in mitral valve.
Even though several studies have revealed the critical roles of
Wnt/signaling pathway in valvulogenesis, no information about the temporal
and spatial distribution of activated β-catenin during valve development is
known. Research work in Chapter 2 characterized the expression profile of
activated β-catenin, which accounts for the Wnt signaling and membrane
bound β-catenin, which mainly functions in maintaining cell-cell adhesion
during valve development. We noticed a reduced nuclear β-catenin expression
beginning at E13.5 and nuclear β-catenin started to relocate from nuclei to
membrane as cardiac valves developed. This process is synchronizing cell
proliferation which is also reduced with development as cardiac cells become
more differentiated and mature[68]. Our study first reports the redistribution
of activated β catenin from nuclei to membrane during valve development
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which is contrast to what we used to think about activated β-catenin. Once
Wnt ligand bind Fz receptor on cell membrane, the deconstruction of β catenin
phosphorylation complex which phosphorylates residues 41,37, and 33 of β
catenin prevents β-catenin from degradation, thus, activated β-catenin is
capable to accumulate in cytosol and has a chance to bind Tcf/Lef1 to recruit
complexes that promote transcriptional activation[56]. The activated βcatenin analyzed here in our study is phosphorylated at Ser552 by Akt which
has been shown to have enhanced β-catenin/Tcf reporter activation[268-270].
However, many other residues in membrane cadherins could enhance the
binding with β-catenin, as well. The local cell-signaling events, kinases and
in vivo phosphorylation of cadherins, β-catenin and Tcf/Lef1 could make this
redistribution significantly diverse during development. The data indicate that
after E11.5, a subset of subendocardial cells start to go through a different
biological process creating a biased affinity of β-catenin to membrane vs.
nuclei.
Another important discovery is that within the developing mitral and
aortic valves, nuclear β-catenin is profoundly downregulated. The activated
nuclear β-catenin is not detectable in adult tissue. This gives rise to the
question that since Wnt/β-catenin signaling is only activated during a
developmental and early neonatal window, how is adult myxomatous
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phenotype is associated with dysregulated Wnt/β-catenin signaling? The
activated nuclear β-catenin was most robust at E11.5 and start to be
downregulated as early as E13.5. This time window is very critical for EMT.
When this downregulation mechanism is not working and β catenin signaling
is not constrained post-EMT, a variety of downstream target genes would be
activated. This process can have lasting consequences throughout a lifetime.
One of the most studied target gene is MMP2, which digest collagen and
versican. The ECM components which are continuously digested by MMPs
would not be proper to support valve tissue. The fragile valve might not be a
problem early in life, but as heart develops and blood volume in cardiac
circulation increases, the sheer force and continuous heartbeat would finally
overwhelm the valve structure and leads to prolapse.
Above all, multiple functional β catenin present on cell membrane and
nuclei is developmentally regulated. Their temporospatial expression pattern
indicate their distinct roles in cell-cell adhesion, transcriptional activity, ECM
deposition during different gestational timepoint. Later studies are needed to
clarify the mechanisms involving those cellular events and take into
consideration of both nuclear and membrane β catenin to cardiac development
and disease.
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The research work in Chapter 3 starts with a genetic mutation in DZIP1
that out lab previously identified within non-syndromic MVP families.
Previous study of our lab has validated the correlation between DZIP1S14R and
myxomatous phenotype. The mechanism of how DZIP1 regulates
valvulogenesis remains unknow. Through proteomics approach, we identified
and confirmed a molecular interaction between DZIP1 and CBY1 and their
spatiotemporal co-localization on mitral valve tissues. CBY1 is a wellestablished ciliary gene which functions in cilia formation[257-261]. On Cby1
deficient valve tissues, we observed shortened and reduced number of primary
cilia which supports those studies. Even though our study firstly validated the
connection between DZIP1 and CBY1, some previous studies have actually
indicated clues of this interaction by showing that both Cby1 and Dzip1
interact with Fam92 to facilitate ciliogenesis[258, 271]. Along with our
previous study on the ciliogenetic function of Dzip1[128], all these evidences
strengthen the cooperative role of Dzip1 and Cby1 in ciliogenesis.
Jean-André Lapart et al. showed that Drosophila Dzip1 is required to
recruit or stabilize Cby1 at centrioles, but does not depend on Cby1 for its
targeting to centrioles[271]. This conclusion gives rise to a hint that the higher
functional hierarchy of DZIP1maintains this collaboration between DZIP1
and CBY1 for ciliogenesis. The following protein stability analysis
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corroborated that CBY1 became less stable in the context of either
DZIP1C604W or DZIP1S14R meanwhile both DZIP1S14R and DZIP1C604W have
impaired protein stability.
Cby1 is also a well-known β-catenin antagonist which is recognized to
compete with Tcf/Lef1 to bind β-catenin and re-locate β-catenin outside
nucleus into cytoplasm[154, 262, 263]. The molecular interaction between
DZIP1 and CBY1 is reminiscent of the possibility that DZIP1 could interact
with β-catenin through CBY1. This assumption was validated by the Co-IP
experiment. Together with the significantly increased nuclear β-catenin from
Dzip1 deficient mitral valve, these data strongly suggested that Dzip1 plays a
vital role in restricting β-catenin signaling through Cby1. The decreased
protein stability of CBY1 under conditions of DZIP1 mutant shed a light for
the mechanism involved in how DZIP1 regulates β-catenin.
From the data collected we propose the following working model
(Figure 4.1). In VICs, DZIP1, CBY1 and β-catenin form a complex which
locates to basal body of a primary cilium. The complex sequesters β-catenin
in cytoplasm. This leads to the shut off of the β-catenin signaling. The ECM
homeostasis is balanced as there would be no extra MMPs induction. When
DZP1 has a mutation, its protein stability is impaired which leads to the
degradation of CBY1. From that, DZIP1-CBY1-β-catenin complex would be
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disrupted. β-catenin will be set free and enter nucleus to start downstream
MMPs transcription. This contributes to ECM digestion. Over time, the valve
tissue become thickened and mechanically incompetent.
In the future this work has the potential to influence therapies for
myxomatous valvular diseases. The peptides used in this work showed
striking effect on β-catenin signaling inhibition. Therapies using Nano
particles which filled with the peptides are appealing for this function. Using
antibody targeted against VICs, these peptides could possibly turn off the
hyperactivated β-catenin signaling in VICs before they produce too much
MMPs to digest collagens.
Many questions remain to be answered and more work is needed to
further elucidate the molecular mechanisms involved in valve disease,
however, considerable progress has been made towards increasing our
knowledge about it. The identification of a complex formed by DZIP1-CBY1β-catenin to regulate Wnt signaling during valvulogenesis is innovative and
opens up the potential for further research to refine our knowledge about the
genetic and molecular landscape of valve development.
.
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Figure 4. 1 Graphic Abstract
DZIP1, CBY1 and β-catenin form a complex which locates to basal body.
This complex sequesters β-catenin in cytoplasm and β-catenin signaling is
being withheld. When Dzip1 has a mutation, its protein stability is impaired
and is not able to stabilize DZIP1-CBY1-β-catenin complex. β-catenin will
be set free and enter nucleus to start downstream MMPs transcription which
contributes to ECM digestion
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Mouse husbandry and genotyping.
Dzip1 conditional mice and Dzip1 knock in mice were genotyped and
generated as previously described[128, 272]. Cby1 mice were a kind gift from
Dr. Ken-Ichi Takemaru. C57Bl6 mice were purchased from Charles river.
Animals were kept in a 12-hour light-dark cycle with food and water ad
libitum. Genotyping was performed by Transnetyx, Inc or inhouse with the
KAPA Mouse Genotyping Kit (Kapabiosystems, #KK7301).
Immunohistochemistry (IHC) and fluorescence imaging.
Immunohistochemical and fluorescence stains were performed on 5 μm,
paraffin-embedded sections from embryonic timepoints (E11.5, E13.5), fetal
gestation (E17.5), neonatal (P0), and adult (6-month). Human mitral valve
samples were processed and sectioned as previously described[181]. Sections
were subjected to antigen unmasking (H‐3300; Vector Laboratories,
Burlingame, CA) and treated for 1 hour at room temperature with a blocking
buffer of PBS (Sigma, St. Louis, MO) containing 1% BSA (Sigma, B428725G). Primary antibodies used were: mouse gamma tubulin (sigma,
T6557,dilution 1:100) rabbit acetylated tubulin (cell signaling, 5335S,dilution
1:100), rabbit Arl13B(Protein tech, 17711-1-AP, dilution 1:500), activated βcatenin (Cell signaling, #9566S, 1:100), total β-catenin (cell signaling,
#9581S, 1:100), MF20 (Developmental Studies Hybridoma Bank, 1:50),
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PCAM-1 (Dianova, #DIA-310, 1:50), hyaluronan binding protein (HABP)
(Calbiochem #385911, 1:100) and LEF1 (cell signaling, #2230S, 1:100). To
determine the activated β-catenin distribution during valvulogenesis, we
stained for β-cateninpS552. Both Akt and PKA were shown to phosphorylate βcatenin at Ser552[268, 273]. Phosphorylation at Ser552 induces β-catenin
accumulation in the nucleus and increases its transcriptional activity [268270]. Specificity of these antibodies were validated as recognizing the
appropriate epitopes in various model systems, including knockout animals
and cell lines[181, 270, 274-277]. Primary antibodies were placed in blocking
buffer overnight at 4°C. Following primary antibody incubations, specimens
were washed five times in PBS and incubated at room temperature with Alexa
Fluor goat α‐rabbit 568 and goat α‐mouse 488 (Invitrogen, Eugene, OR)
diluted 1:100 in PBS. Nuclei were stained with Hoechst dye (1:10,000;
Invitrogen) in PBS for 5 min prior to the final washes in PBS. All samples
were cover‐slipped using Dabco mounting medium (Sigma). Images of
immunostained sections were captured with Zeiss Axioimager M2 and Leica
TCS SP5 AOBS Confocal Microscope System (Leica Microsystems, Inc., 410
Eagleview Boulevard, Suite 107, Exton, PA 19341). Z-stacks were set by
finding the highest and lowest depth with visible fluorescence and using the

151

system optimized setting to determine steps. Z-stacks were then compiled to
form maximum projection images[129].N>3/timepoint or genotypes.
Yeast 2 Hybrid Screen
Y2H screens were performed by Hybrigenics Services (Paris, France;
www.hybrigenics-services.com). The coding sequence of the full-length
Homo sapiens DZIP1 (isoform 2) was PCR-amplified and cloned in frame
with the LexA DNA binding domain (DBD) into plasmid pB27 as a Cterminal fusion to Gal4 (Gal4-bait fusion). The DZIP1-DBD bait protein was
used to screen a human embryonic and adult cardiac library. A total of 274
prey fragments of the positive clones were amplified by PCR and sequenced
at their 5’ and 3’ junctions.
Interaction confidence scoring
Predicted Biological Score (PBS) was attributed to each interaction as
previously described[278]. The PBS score represents the probability of an
interaction being non-specific which is primarily based on the comparison
between the number of independent prey fragments found for an interaction
and the chance of finding them at random (background noise). The value in
the scores A to D varies between 0 and 1 (A < 1e-10 < B < 1e-5 < C < 1e-2.5
< D < 1). Several thresholds were arbitrarily defined in order to rank the
results in the following scores:
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A: Very high confidence in the interaction.
B: High confidence in the interaction.
C: Good confidence in the interaction.
D: Moderate confidence in the interaction.
E: Interactions involving highly connected (or relatively highly connected)
prey domains, warning of non-specific interaction.
F: Experimentally proven technical artifacts.
Generation of Dzip1 expression constructs and TAT-fusion peptides
Control human DZIP1-Myc-DDK plasmid was purchased from Origene
(clone ID: 198968). Truncated DZIP1 plasmids were sub-cloned with a HA
tag sequence at the C terminus using pTARGETTM Mammalian Expression
Vector System (Promega, Cat No: A1410). The Dzip1 mutation was
incorporated through a QuickChange II XL Site-Directed Mutagenesis Kit
(Agilent Technologies) based on the manufacturer’s recommendations and
had a HA-epitope tag at the C terminus. CBY1 plasmid with a HA-epitope tag
at C terminus was purchased from Sino Biological (clone ID: BC016139).
CBY1 plasmid with a Flag-epitope flag at the C terminus was a kind gift from
Dr.Ken-Ichi Takemaru and described previously[258].All clones were
sequenced through Genewiz before use. TAT-fusion peptides were
synthesized by Genescript with biotin at C terminus and FAM at N terminus.
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Cell culture
Human valvular cells were isolated and cultured in DMEM with 15%
fetal calf serum and antibiotics (P/S, fungizone) as described previously[181].
Chicken valvular interstitial cells (cVICs) were isolated from anterior leaflet
of chicken embryos at HH40 as described before[279]. cVICs were
maintained in Medium 199 (M199, Invitrogen) containing 5% of chicken
serum (bioworld),0.1% ITS (gibco,41400-045) and 1% antibiotics (P/S,
fungizone). Dzip1S14R/+ or wild type mouse embryonic fibroblast(MEFs) were
derived according to the protocol published before[280] and were cultured in
DMEM with 10% FBS and antibiotics (P/S, fungizone). For all experiments,
these valvular interstitial cells were utilized prior to passage 5. Hek293T cells
were maintained in DMEM with 10% fetal bovine serum and antibiotics (P/S,
fungizone).
Primary cilia measurement
For measuring the cilia length in the Cby1 control (Cby1+/+) versus
Cby1+/-, values were plotted every 0.5 μm to assess cilia length distribution
differences between the two genotypes at P0. We chose 3 slides from each
animal, and imaged three pictures at different parts on anterior leaflets (tip,
middle, root). 3 or 4/genotype were included. Cilia length measurements were
performed using Z-stack images of anterior leaflet stained with acetylated
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alpha tubulin/arl13b, gamma tubulin and counterstained with Hoechst. Zstack images were then imported into Imaris software and measurements were
taken from the base to the tip of the axoneme. All cilia in the field of view
were measured. For control mitral leaflets, a total of n=1266 cilia lengths
quantified. For Cby1+/-mitral leaflets a total of n=497 cilia lengths
quantified[128]. Cell numbers from each image were counted blindly by two
people. n=26 images were counted from wild type and n=25 images were
counted from Cby1+/-.
Co-IP and Western blotting
Hek 293T cells were seeded at 5X105 /well on 6-well plates one day
before transfection. Cells were co-transfected with DZIP1 and CBY1
plasmids using FuGENE HD transfection Reagent (Promega, Cat No: E2311)
for 72 hours and were lysed using ice-cold lysis buffer (25mM Tris HCL,
150mM Nacl, 1% NP-40,5% glycerol) with Halt protease and phosphatase
Inhibitor cocktail(100x) being added before (Thermo Scientific, Cat
NO:78440, dilution 1:500) followed by incubating on ice for 30 minutes with
intermittent vortex. Preclearing of the cell lysates were done by adding 2.5 ul
of IgG with the same species as primary antibody and 25ul of Pierce Protein
A/G Agarose beads (Thermo Scientific, Cat NO:20421) into cell lysates
containing 400ug protein and rotating for 2 hours at 4℃. 5ul of primary
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antibody or IgG together with 50ul of Pierce Protein A/G Agarose beads were
incubated with cell lysates at 4 ℃ overnight. Beads were collected and washed
with 1ml of ice-cold lysis buffer for 5 times before SDS-PAGE. For peptide
Co-IP, HEK293T or human valvular interstitial cell lysates were incubated
with Pierce Streptavidin Magnetic Beads (Pierce, Cat NO:88816) and
biotinylated peptide at 4 ℃ overnight. Collect and wash magnetic beads
according manufacture’s manual before SDS-PAGE. The primary antibodies
used for Co-IP assays and Western blotting were as follows: mouse Flag M2
(Sigma,dilution 1:1,000), rabbit HA (Sigma,Cat NO:SAB4300603, dilution
1:1,000).rabbit CBY1(Protein tech, Cat NO: 12239-1-AP, dilution 1:1,000),
rabbit β catenin(cell signaling, Cat NO: 9581, dilution 1:1,000). Horseradish
peroxidase (HRP)-conjugated secondary antibodies were purchased from
Sigma (dilution 1:10,000).
Computational Studies:
RaptorX Structure Alignment was used to align the protein structures of
interest: P5 wild type (WT), P5 C585W mutant, P2 WT[281, 282]. RaptorX
employs a statistical learning method to calculate the compatibility between a
target sequence and a template structure [283]. Protein structures were
prepared using PEP-FOLD 3: a publicly available software capable of de novo
peptide tertiary structure prediction from amino acid sequences [284-286].
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Protein structures were exported as PDB files and submitted for analysis by
the RaptorX Structure Alignment Server. RaptorX calculates the structural
similarity of two or more proteins by comparing the length of the core (Lali),
root mean squared deviation (RMSD), and template modeling score (TM
score). For multiple structure alignment (MSA), Lali is the length of core,
which consists of all the fully aligned columns [281, 282]. The RMSD is
calculated only on the core residues. The TM score is the measure of similarity
between two or more protein structures with different tertiary structures. The
TM Score ranges from 0-1.0: If TM score >0.6, there is a 90% chance that
two proteins share a similar fold. When TM score <0.4, there is a 90% chance
that two proteins have different folds.
Peptide treatment and reporter assay in cVICs
cVICs were seeded at 5X105 /well on 6-well plates. The next day, cells
were transfected with 1.6μg TopFlash (Addgene plasmid # 12456) or
FopFlash (Addgene plasmid # 12457) and 0.4 μg b-galactosidase-encoding
construct. Transfections were performed using FuGENE HD transfection
Reagent (Promega, Cat No: E2311) and cells were incubated at 37℃ for 24
hours. TAT-fusion peptide was added at 10 μM or 1 μM 24 hours post
transfection. Cells were harvested the next day after two times of 1XPBS wash
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and firefly luciferase activities were evaluated using the Luciferase Assay
System (Promega, E1500).
Protein stability analysis
HEK293T cells were seeded at 5x105 /well on 6-well plate. On the next
day, cells were co-transfected with wild type DZIP1-Flag or DZIP1C604W-Flag
and CBY1-HA constructs using FuGENE HD transfection Reagent (Promega,
Cat No: E2311). Cycloheximide were added 48 hours post transfection at
concentration of 100ng/ml. Cells were lysed with RIPA buffer at 0/4/8/16/32
hours after cycloheximide treatment. Dzip1S14/+ and wild type MEFs were
seeded at 2X105/well on 6-well plate and treated with cycloheximide at
concentration of 100ng/ml the next day. Cell lysates were harvested using
RIPA buffer at 0-

and 48-hours post

cycloheximide treatment.

Immunoblotting was performed as described previously[181]. Primary
antibody used for western blotting were as follows: mouse Flag M2 (Sigma),
rabbit HA (Sigma, Cat NO: SAB4300603), rabbit CBY1(Protein tech, Cat NO:
12239-1-AP), rabbit DZIP1 (Protein tech, Cat NO: 13779-1-AP), mouse actin
(Millipore, Cat No: MAB1501). HRP-conjugated secondary antibodies were
purchased from Sigma.
Nuclear and Cytoplasmic extraction
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Dzip1S14R/+ and wild type MEFs from E13.5 embryos were plated at
2x105 /well on 6-well plate. On the next day, cells were digested with trypsin
and washed with 1x PBS twice and fragmentation was done following the
instruction of NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo, Cat NO:78835). Nuclear and cytoplasmic extractions were collected
for Western Blotting. β-Catenin was normalized by total protein indicated by
Ponceau S.
Human studies
All studies involving human research were approved by the Institutional
Review Board Institut du Thorax, Nantes, France and all participants provided
written informed consent.
Familial genetics and WES
Exome sequencing was performed on the proband (II.4). Exome capture
was carried out using the SureSelect Human All Exon System using the
manufacturer’s protocol version 1.0 (Agilent Inc.) that is compatible with
Illumina paired-end sequencing. Exome-enriched genomes were multiplexed
by flow cell for 101-bp paired-end read sequencing according to the protocol
for the HiSeq 2000 sequencer (version 1.7.0; Illumina) to allow a minimum
coverage of 30Å~. Reads were aligned to the human reference genome
(UCSC NCBI36/hg19) using the Burrows- Wheeler Aligner (version 0.5.9).
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Quality control to determine sample and genotyping quality and to potentially
remove poor SNPs and/or samples was performed as we have previously
published[181]. Follow up Sanger sequencing was performed on the rest of
the family to confirm phenotype-genotype correlation of the identified DZIP1
SNP.
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